

ZENIA ΣΑΡΙΔΑΚΗ - ΖΩΡΑ
ΑΝΑΛΥΤΙΚΟ ΒΙΟΓΡΑΦΙΚΟ

Metropolitan Hospital, Αθήνα • «Ασκληπιός ΔΙΑΓΝΩΣΙΣ», Ηράκλειο Κρήτης •
Ιδιωτική Κλινική «Ασκληπιείον Κρήτης», Ηράκλειο Κρήτης • Ιδιωτικό Ιατρείο,
Πλουτάρχου 17, Κολωνάκι

Προφίλ



Η Δρ. Ζένια Σαριδάκη - Ζώρα είναι **Παθολόγος Ογκολόγος**, Διευθύντρια στην Α΄ Ογκολογική Κλινική του Metropolitan Hospital. Αποφοίτησε από την **Ιατρική Σχολή του Πανεπιστημίου Κρήτης**, ειδικεύτηκε στην Παθολογική Ογκολογία και μετεκπαιδεύτηκε στο **University of Oxford** και στο **Katholieke Universiteit Leuven (Βέλγιο)**, όπου υπηρέτησε ως μεταδιδακτορική ερευνήτρια στο Center for Human Genetics και στο Department of Digestive Oncology.

Έχει διατελέσει **Πρόεδρος της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ)** για δύο συνεχόμενες θητείες (2021–2023, 2023–2025), ούσα η **πρώτη γυναίκα στην ιστορία της Εταιρείας** που ανέλαβε αυτή τη θέση, και έχει υπηρετήσει ως εκλεγμένο μέλος του Διοικητικού Συμβουλίου επί έξι συνεχείς θητείες (2013–2025).

Το 2022 (20/12/2022) ορίστηκε από την ηγεσία του Υπουργείου Υγείας ως **Συντονίστρια της Ομάδας Εργασίας για τη δημιουργία του Εθνικού Μητρώου Ασθενών με Νεοπλασματικές Ασθένειες**, συμβάλλοντας καθοριστικά στο σχεδιασμό και την υλοποίηση του Εθνικού Μητρώου Νεοπλασματικών Νόσων και στον ψηφιακό μετασχηματισμό της ογκολογικής φροντίδας στη χώρα μέσω του ηλεκτρονικού φακέλου των ογκολογικών ασθενών. Επίσης, συνεργάστηκε με την Πολιτεία, μεταξύ πολλών άλλων, για την ικανοποίηση του πάγιου αιτήματος ασθενών και ιατρών για την **επικαιροποίηση της αποζημιούμενης λίστας βιοδεικτών από τον ΕΟΠΥΥ (10/2025)** υλοποιώντας ένα καθοριστικό βήμα για την ισότιμη πρόσβαση των ασθενών σε καινοτόμες θεραπείες.

Σε διεθνές επίπεδο, κατέχει δύο σημαντικές θέσεις στην **ASCO (Αμερικανική Εταιρεία Κλινικής Ογκολογίας)**: είναι επικεφαλής του **Central and Eastern Europe (CEE) Regional Council** (επανεκλογή στη θέση αυτή στις 30/10/2025) και μέλος του **ASCO Global Guidelines Advisory Group της (ASCO)**. Είναι, επίσης, μέλος του **Advisory Board του Ευρωπαϊκού Οργανισμού κατά του Καρκίνου (ECO)** για το έργο #INTERACTEUROPE100, καθώς και μέλος της **European Society for Medical Oncology (ESMO)**. Είναι συνιδρύτρια και μέλος της Συντονιστικής Επιτροπής των **Women for Oncology – Γυναίκες στην Ογκολογία (W4O Hellas)**.

Διαθέτει σημαντική ερευνητική και εκπαιδευτική δραστηριότητα με **62 δημοσιεύσεις σε διεθνή επιστημονικά περιοδικά, περισσότερες από 3.100 αναφορές και h-index 27, total impact factor 867, και πολυάριθμες επιστημονικές ανακοινώσεις και ePosters που έχουν παρουσιαστεί σε διεθνή συνέδρια**, όπως ESMO, ASCO, ESMO Breast Cancer και ESMO Gastrointestinal Cancers. και έχει διακριθεί από την ASCO με Certificate of Appreciation για τη συμβολή της στο διεθνές εκπαιδευτικό πρόγραμμα ECHO Health After Cancer.

Με πολυετή κλινική, ερευνητική και εκπαιδευτική δραστηριότητα, η Δρ. Ζένια Σαριδάκη αποτελεί μία από τις πλέον αναγνωρισμένες μορφές της σύγχρονης ελληνικής ογκολογίας, με ενεργό παρουσία στην προώθηση της επιστημονικής εκπαίδευσης, της διεθνούς συνεργασίας και της ενδυνάμωσης των γυναικών στην ιατρική κοινότητα.

Εκπαίδευση - Μετεκπαίδευση – Διπλώματα

Προπτυχιακές σπουδές

- Ιατρική Σχολή Πανεπιστημίου Κρήτης, Τμήμα Επιστημών Υγείας (1991–1997), Βαθμός Πτυχίου: 8,01/10.

Προπτυχιακή τρίμηνη κλινική δραστηριότητα μέσω του προγράμματος ERASMUS:

- Κλινική Πνευμονολογίας, *Hôpital Civil de Strasbourg, Université Louis-Pasteur, Faculté de Médecine de Strasbourg* (France, 1994).
- Κλινική Παιδιατρικής, *Hôpital Universitaire des Enfants "Reine Fabiola", Université Libre de Bruxelles, Faculté de Médecine* (Belgique, 1996).

Μεταπτυχιακές σπουδές

- Διδακτορική Διατριβή (PhD) στην Ιατρική Σχολή Πανεπιστημίου Κρήτης (1997–2002), Τίτλος: «Γενετική ανάλυση της αλληλουχίας μικροδορυφορικού DNA σε δερματικές νεοπλασματικές αλλοιώσεις».

Επιβλέπων: Καθ. Δ.Α. Σπαντίδος.

Βαθμός: Άριστα.

Ειδικότητα

- Ειδικότητα Παθολογικής Ογκολογίας, Πανεπιστημιακό Νοσοκομείο Ηρακλείου (ΠαΓΝΗ), Κρήτη (1999–2007).
 - Περιλαμβάνει 6 μήνες ειδικότητα Αιματολογίας.
 - Εκπαίδευση στην Ακτινοθεραπεία, Κλινική Ακτινοθεραπείας ΠαΓΝΗ (12/2006–01/2007).
 - Τίτλος ειδικότητας Παθολογικής Ογκολογίας (24/09/2007).

Μετεκπαίδευση

- *Academic visitor* στο Oxford University, Medical Oncology Unit of the Churchill and John Radcliffe Hospitals και στο Department of Clinical Pharmacology in the Radcliffe Infirmary, υπό την επίβλεψη του Professor David J. Kerr (Φεβρουάριος–Ιούνιος 2007).
- European Certification in Medical Oncology (ESMO Examination) (Σεπτέμβριος 2007–2012).

- Μεταδιδακτορική ερευνήτρια πλήρους απασχόλησης στο *Center for Human Genetics O&N1, Katholieke Universiteit Leuven* και στο *Department of Digestive Oncology, University Hospital Gasthuisberg Leuven, Belgium* (01/12/2010–30/11/2011). Επιβλέπουσα: Prof. Sabine Tejpar.
- Ερευνητική υποτροφία ΕΟΠΕ για τη μεταδιδακτορική απασχόληση στο εξωτερικό (2010–2011).
- Επιστημονική Συνεργάτιδα της Πανεπιστημιακής Παθολογικής - Ογκολογικής Κλινικής ΠαΓΝΗ και μεταδιδακτορική ερευνήτρια στο Εργαστήριο Βιολογίας του Καρκίνου, Ιατρική Σχολή Πανεπιστημίου Κρήτης (2012–2014).
- Ολοκλήρωση του INTERACT-EUROPE 100 Inter-Specialty Cancer Training Programme – Trainers’ Course, European Cancer Organisation (ECO), συνολικής διάρκειας 125 ωρών – Micro-credential, EQF Level 7, 5 ECTS και 125 CME/CPD credits (2026).

Ξένες γλώσσες

- Αγγλικά (άριστα)
- Γαλλικά (άριστα)

Μέλος Επιστημονικών Εταιρειών

- **τ. Πρόεδρος της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) για δύο συνεχόμενες θητείες** (2021–2023, 2023–2025) η πρώτη γυναίκα που εκλέγεται σε αυτήν τη θέση στην ιστορία της Εταιρείας και η νεότερη σε αυτή τη θέση. Εκλεγμένο μέλος στο **Δ.Σ. της Εταιρείας για έξι συνεχείς θητείες** (από το 2013–2025) και μέλος από το 2008 έως σήμερα.
- Μέλος της **Ελληνικής Συνεργαζόμενης Ογκολογικής Ομάδας (HeCOG)** από το 2017 έως σήμερα **συν-συντονίστρια της ομάδας GI**.
- Μέλος από το 2023 του **Central and Eastern Europe (CEE) Regional Council της Αμερικανικής Εταιρείας Κλινικής Ογκολογίας (ASCO)** και από το 2025 **Επικεφαλής** του (επανεκλογή στη θέση αυτή 30/10/2025). Είναι μέλος του **Global Guidelines Advisory Group (GAG) της ASCO από το 2024 έως σήμερα**.
- Είναι μέλος της **Ευρωπαϊκής Εταιρείας Παθολογικής Ογκολογίας (ESMO)** από το 2003 (αρχικά ως junior member και στη συνέχεια πλήρες μέλος), ενώ εκπροσώπησε την Ελλάδα ως μέλος της **National Societies Committee** της Εταιρείας (2022 – 2025).
- Μέλος του **Advisory Board του Ευρωπαϊκού Οργανισμού κατά του Καρκίνου (ECO)** για το έργο #INTERACTEUROPE100 (από τον Ιούλιο 2024), (2026) Ολοκλήρωση υπό τον συντονισμό της του **INTERACT-EUROPE 100 Inter-Specialty Cancer Training Programme – Trainers’ Course** του **European Cancer Organisation (ECO)** στο **Metropolitan Hospital**.
- Συνιδρύτρια και μέλος της Συντονιστικής Επιτροπής των **W4O Hellas – Γυναίκες στην Ογκολογία** από το 2014 έως σήμερα.

Εκπαιδευτικό Έργο

Μακροχρόνια συμμετοχή στην ιατρική εκπαίδευση και στη δια βίου μάθηση στην ογκολογία.

Έχει διατελέσει εισηγήτρια, συντονίστρια και προσκεκλημένη εκπαιδεύτρια σε πολυάριθμα προγράμματα συνεχιζόμενης ιατρικής εκπαίδευσης, ημερίδες και εκπαιδευτικά σεμινάρια της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ), της Ευρωπαϊκής Εταιρείας Παθολογικής Ογκολογίας (ESMO) και της Αμερικανικής Εταιρείας Κλινικής Ογκολογίας (ASCO).

Από τον Ιανουάριο 2025 έχει αναγνωριστεί με **Certificate of Appreciation** από την **ASCO & International Education Steering Group** για τη συμβολή της ως μέλος της Planning Committee and Faculty στο διεθνές εκπαιδευτικό πρόγραμμα **ECHO Health After Cancer** που υλοποιήθηκε για πρώτη φορά στην Ελλάδα.

Κατά τη διάρκεια της θητείας της στην προεδρία της ΕΟΠΕ, εγκαινιάστηκε επίσης το **Μνημόνιο Συνεργασίας της ΕΟΠΕ (2023) με το Ελληνικό Ανοικτό Πανεπιστήμιο (ΕΑΠ) για την Ελληνική Ακαδημία Ογκολογίας (ΕΑΚΟ)** — τον θεμελιώδη εκπαιδευτικό θεσμό της ΕΟΠΕ που αναβαθμίστηκε σε Πρόγραμμα Βραχείας Μετεκπαίδευσης του ΕΑΠ, ενταγμένο στο Κέντρο Επιμόρφωσης και Δια Βίου Μάθησης του Πανεπιστημίου, και οδηγεί σε Πιστοποιητικό Εξειδικευμένης Επιμόρφωσης.

Κλινικό Έργο

Διευθύντρια στην Α' Ογκολογική Κλινική, Metropolitan Hospital, Νέο Φάληρο, Αθήνα (2022 έως σήμερα).

Υπεύθυνη για την παρακολούθηση, διάγνωση και θεραπεία ογκολογικών ασθενών σε όλο το φάσμα των νεοπλασματικών νόσων. Η Κλινική καλύπτει όλο το πεδίο της Παθολογικής Ογκολογίας, συμπεριλαμβανομένων των **στοχευμένων θεραπειών, ανοσοθεραπειών, των κλασικών και καινοτόμων χημειοθεραπειών, της υποστηρικτικής αγωγής, της γενετικής συμβουλευτικής**. Επίσης, η κλινική τρέχει **μια σειρά Κλινικών Μελετών στις οποίες συμμετέχει ως PI και SI**, δίνοντας την δυνατότητα στους ογκολογικούς ασθενείς να λάβουν ό,τι πιο νέο και καινοτόμο υπάρχει στον τομέα της θεραπευτικής στην ογκολογία.

Επιστημονική Υπεύθυνη, Ογκολογικό Τμήμα «Ασκληπιός Διάγνωσης», Ηράκλειο Κρήτης (2012 έως σήμερα) & Συνεργάτης, Ιδιωτική Κλινική «Ασκληπιείον Κρήτης», Ηράκλειο Κρήτης (2012 έως σήμερα).

Υπεύθυνη για τη διάγνωση, θεραπεία και παρακολούθηση ογκολογικών ασθενών με όλα τα νεοπλασματικά νοσήματα, στο πλαίσιο διεπιστημονικής συνεργασίας με άλλες ιατρικές ειδικότητες. Ανάπτυξη εξατομικευμένων θεραπευτικών πρωτοκόλλων και εισαγωγή καινοτόμων πρακτικών παρακολούθησης. Παροχή εξειδικευμένων ογκολογικών θεραπευτικών υπηρεσιών στο πλαίσιο της συνεργασίας με την Κλινική, με έμφαση στη διεπιστημονική προσέγγιση και στη συνεχή επικαιροποίηση των θεραπευτικών πρακτικών με βάση τα διεθνή πρωτόκολλα. Σχεδιασμός της κατάλληλης θεραπευτικής στρατηγικής, με χημειοθεραπεία, ανοσοθεραπεία και στοχευμένες θεραπείες. Αξιολόγηση μοριακών εξετάσεων και βιοδεικτών για την εφαρμογή της ιατρικής ακριβείας και παροχή γενετικής συμβουλευτικής όπου

ενδείκνυται. Καθοδήγηση του ασθενούς σε κάθε στάδιο της νόσου. Μακροχρόνια παρακολούθηση και ανθρωποκεντρική προσέγγιση.

Από το 2026, **Ιδιωτικό ιατρείο στην Αθήνα**, Πλουτάρχου 17, Κολωνάκι. Παρακολούθηση και εξατομικευμένη θεραπευτική αντιμετώπιση ασθενών με όλες τις νεοπλασματικές νόσους σε ένα περιβάλλον ολιστικής φροντίδας. Δίνοντας βάρος στην ενδυνάμωση σώματος και πνεύματος, διαφοροποιούμε τις στρατηγικές μας ανάλογα με τις ανάγκες του κάθε ασθενούς.

Ακαδημαϊκή Δραστηριότητα

Άμισθη Επιστημονική Συνεργάτης, Πανεπιστημιακή Παθολογική – Ογκολογική Κλινική, Πανεπιστημιακό Νοσοκομείο Ηρακλείου Κρήτης (ΠαΓΝΗ) (2012–2014). Συμμετοχή σε ερευνητικά ογκολογικά προγράμματα και εκπαίδευση ειδικευομένων ιατρών.

Μεταδιδακτορική Ερευνήτρια, Εργαστήριο Βιολογίας του Καρκίνου, Ιατρικό Τμήμα, Πανεπιστήμιο Κρήτης (2007–2010).

Συμμετοχή σε **κλινικές και εργαστηριακές μελέτες και πρωτόκολλα** στο πεδίο της Παθολογικής Ογκολογίας.

Academic visitor στο Oxford University, Medical Oncology Unit of the Churchill and John Radcliffe Hospitals και στο Department of Clinical Pharmacology in the Radcliffe Infirmary, υπό την επίβλεψη του Professor David J. Kerr (Φεβρουάριος–Ιούνιος 2007).

Μεταδιδακτορική Επιστημονική Ερευνήτρια (πλήρους απασχόλησης), Center for Human Genetics O&N1 και Department of Digestive Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Βέλγιο (2010–2011) με **ερευνητική δραστηριότητα** υπό την επίβλεψη της Professor Sabine Tejpar, στη γονιδιακή έκφραση και τα μοριακά χαρακτηριστικά των νεοπλασμάτων γαστρεντερικού.

Ερευνητικό Έργο

- Κλινική και μεταφραστική έρευνα στον καρκίνο του παχέος εντέρου, του μαστού, του στομάχου, του παγκρέατος και του πνεύμονα.
- Ερευνητική δραστηριότητα στον τομέα των βιοδεικτών πρόγνωσης και πρόβλεψης ανταπόκρισης στη θεραπεία σε συμπαγείς όγκους.
- Μελέτη μηχανισμών ανθεκτικότητας σε στοχευμένες θεραπείες και ανοσοθεραπείες.
- Ενσωμάτωση μοριακών και γενετικών χαρακτηριστικών στην εξατομικευμένη θεραπευτική προσέγγιση.
- Από το 2017 έως σήμερα **Μέλος της ομάδας κλινικής και εφαρμοσμένης έρευνας Ελληνική Συνεργαζόμενη Ογκολογική Ομάδα (HeCOG) και συν-συντονίστρια της ομάδας GI**

- Συμμετοχή σε ερευνητικά προγράμματα και κλινικές δοκιμές φάσης I–III στο Πανεπιστήμιο Κρήτης, στο University Hospital Gasthuisberg (Leuven, Belgium) και σε διεθνείς συνεργασίες.
- **Μεταδιδακτορική έρευνα στο *Center for Human Genetics* και στο *Department of Digestive Oncology* (Katholieke Universiteit Leuven),** υπό την επίβλεψη της Professor Sabine Tejpar, με αντικείμενο τη γονιδιακή έκφραση και τα μοριακά χαρακτηριστικά των νεοπλασμάτων γαστρεντερικού.
- ***Academic visitor* στο Oxford University, Medical Oncology Unit of the Churchill and John Radcliffe Hospitals και στο Department of Clinical Pharmacology in the Radcliffe Infirmary,** υπό την επίβλεψη του Professor David J. Kerr (Φεβρουάριος–Ιούνιος 2007).
- Συνεργαζόμενη ερευνήτρια στο Εργαστήριο Βιολογίας του Καρκίνου της Ιατρικής Σχολής του Πανεπιστημίου Κρήτης με αντικείμενο τη μοριακή παθογένεια νεοπλασματικών νοσημάτων.
- Υπότροφος ερευνητικής υποτροφίας της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) για μεταδιδακτορική απασχόληση στο εξωτερικό.

Βραβεία – Υποτροφίες

- **Certificate of Appreciation από την *American Society of Clinical Oncology (ASCO)* και το *International Education Steering Group* (2025)** για τη συμβολή της ως μέλος της *Planning Committee* και *Faculty* του διεθνούς εκπαιδευτικού προγράμματος **ECHO Health After Cancer**, κατά την υλοποίησή του στην Ελλάδα.
- **Υπότροφος Μεταδιδακτορικής Έρευνας στο *Center for Human Genetics O&N1* και στο *Department of Digestive Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven,* Βέλγιο με Ερευνητική Υποτροφία από την Εταιρεία Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) για ένα έτος μεταδιδακτορικής απασχόλησης στο εξωτερικό (2010–2011).**

Ερευνητικό Συγγραφικό Έργο

Συγγραφέας ή συν-συγγραφέας σε **62 άρθρα σε αναγνωρισμένα peer-reviewed επιστημονικά περιοδικά** (3,171 citations; h-index 27; i10-index 43; total impact factor 867) και σε πολυάριθμες επιστημονικές ανακοινώσεις και e-Posters που έχουν παρουσιαστεί σε διεθνή συνέδρια, όπως **ESMO, ASCO, ESMO Breast Cancer και ESMO Gastrointestinal Cancers**. Το συγγραφικό της έργο επικεντρώνεται σε θεματικές που αφορούν **στον καρκίνο του μαστού, του πνεύμονα, του γαστρεντερικού, την ανοσοθεραπεία, την πρόγνωση μέσω βιοδεικτών και την εξατομικευμένη ιατρική προσέγγιση στη θεραπεία του καρκίνου.**

Υπήρξε **Deputy Managing Editor** του επίσημου αγγλόφωνου περιοδικού της ΕΟΠΕ, **Forum of Clinical Oncology (FCO)** (2014-2017)

Επιστημονικές δημοσιεύσεις

Άρθρα σε διεθνή περιοδικά με impact factor:	
1.	Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the VELOUR trial <i>NPJ Precision Oncology</i> , 2026;10(1):50.
2.	Understanding exceptional response: The role of MINDY1 SNP in CDK4/6 inhibitor therapy for ER+, HER2– advanced breast cancer, Eleni Balla, Yi Li, Zikun Zhou, John T. Nguyen, Kyriaki Papadopoulou, Evangelia Razis, Angelos Koutras, Eleni Galani, Giannis Mountzios, Ourania Romanidou, George Fountzilas, Athina Christopoulou, Dimitris Tryfonopoulos, Panagiota Oikonomopoulou, Zenia Saridaki, Anna Koumarianou, Elena Fountzilas, Leonidas Bleris. <i>Human Genetics and Genomics Advances</i> , 2026;7(1):100560.
3.	Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece <i>ESMO Gastrointestinal Oncology</i> , 2025;8:100153.
4.	Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study <i>ESMO Real World Data and Digital Oncology</i> , 2025;7:100095.
5.	Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer <i>ESMO Gastrointestinal Oncology</i> , 2024;5:100073.
6.	Empowering Primary Care Providers (PCPs) in Cancer Survivorship: Insights from the ASCO HeSMO Project ECHO in Greece. Tsoukalas N., Razis E., Boukovinas I., Lionis C., Chatzifoti N., Eaton V., Gould A., Kremzier M., Sarchet V., Schapira L., Saridaki Z. (2025). Presentation No. 3192eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. (Abstract accepted; to be published in Annals of Oncology Supplement.)
7.	The landscape of PIK3CA mutations and their prognostic impact on recurrence in HR+/HER2- breast cancer: A real-world multicenter analysis. Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. Boutis A., Nikolaou M., Ardavanis A., Zagouri F., Koumarianou A., Timotheadou E., Tolis C., Christopoulou A., Korantzis I., Kampletsas E., Lontos M., Loga K., Kesisis G., Biziota I., Papatsimpas G., Karageorgopoulou S., Antoniadou K., Chatzifoti N., Saridaki Z. (2025). Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. (Abstract accepted; to be published in Annals of Oncology Supplement.)
8.	Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrris, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A Vagionas, P Papakostas, A

	Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology, 5, 1073, https://doi.org/10.1016/j.esmogo.2024.100073
9.	Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study, E Fountzilas, S Karageorgopoulou, G Karakatsoulis, D Tryfonopoulos, K Papazisis, A Koutras, A Koumarianou, G Zafeiri, E Bizioti, A Nikolaidi, I Boukovinas, E Vrana, D Mauri, E Aravantinou-Fatorou, E Razis, E Vorrias, Z Saridaki, D Bafaloukos, A Christopoulou, A Boutis, N Tsoukalas, S Stamatopoulou, N Spathas, M Theochari, F Zagouri, A Psyrris, G Fountzilas, E Lalla,
10.	Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report, Zacharenia Saridaki, Elena Fountzilas, Athanasios Alexopoulos, Niki Karachaliou, BMC Medical Genomics
11.	Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece, S Manolakou, N Tsoukalas, E Saloustros, T Makatsoris, I Boukovinas, A Christopoulou, A Karampeazis, I Bompolaki, I-I Varthalitis, E Voulgaris, K Ballasis, A Boutis, E Galani, C Kalofonos, A Koumarianou, C Kourousis, P Papakotoulas, C Papandreou, E-I Perdikouri, A Andreadou, I Athanasiadis, F-I Dimitrakopoulos, C Emmanouilidis, E Kampletsas, O Katopodi, P Kosmidis, K Koutsoukos, E Lianos, P Makrantonakis, E Ntouvelis, C Panopoulos, V Papadopoulos, G Pentheroudakis, E Samantas, I Stoupis, G Tsironis, N Chatzifoti, I Souglakos, Z Saridaki, ESMO Gastrointestinal Oncology, 8, 100153,
12.	Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrris, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A Vagionas, P Papakostas, A Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology 5, 100073
13.	Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, Journal of Clinical Oncology 42 (16_suppl), 3146-3146
14.	Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer., Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilas, Natalia Chatzifoti, Zacharenia Saridaki, Journal of Clinical Oncology 42 (16_suppl), e23139-e23139

15.	Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial., Ting Pu, Allyson Peddle, Pratyaksha Wirapati, Yourae Hong, Leslie Samuel, Jayesh Desai, Maigo Riener, Zacharenia Saridaki, David Cunningham, Sabine Tejpar, Petros Tsantoulis, Journal of Clinical Oncology 42 (16_suppl), 3592-3592
16.	Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns, Elena Fountzilas, Theofanis Papadopoulos, Eirini Papadopoulou, Cedric Gouedard, Helen P Kourea, Pantelis Constantoulakis, Christina Magkou, Maria Sfakianaki, Vassiliki Kotoula, Dimitra Bantouna, Georgia Raptou, Angelica A Saetta, Georgia Christopoulou, Dimitris Hatzibougias, Electra Michalopoulou-Manoloutsiou, Eleni Siatra, Eleftherios Eleftheriadis, Evangelia Kavoura, Loukas Kaklamanis, Antigoni Sourla, George Papaxoinis, Kitty Pavlakis, Prodromos Hytioglou, Christina Vourlakou, Petroula Arapantoni-Dadioti, Samuel Murray, George Nasioulas, Grigorios Timologos, George Fountzilas, Zacharenia Saridaki, Diagnostics 14 (11), 1076
17.	Complete response as prognostic marker of prolonged survival in metastatic melanoma, D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, EJC Skin Cancer 2
18.	Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer., Georgios Pappas, Nikolaos Tsoukalas, Anastasios L Boutis, Emmanouil S Saloustros, Ioanna Gazouli, Stefania Gkoura, Roubini Zakopoulou, Chrysovalantis Aidarinis, Ioannis Boukovinas, Anna Koumarianou, Stefania Kokkali, Georgios Gkoumas, Panagiotis J Vlachostergios, Avraam Assi, Athanasios Karampeazis, Adamantia Nikolaidi, Elena Fountzilas, Natalia Chatzifoti, Zacharenia Saridaki Journal of Clinical Oncology Volume 42, Number 16_suppl https://doi.org/10.1200/JCO.2024.42.16_suppl.e23139
19.	Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., Emmanouil S Saloustros, Michael Lontos, Eleni Timotheadou, Charalampos Andreadis, Efthymia Skafida, John Syrios, Antonia Kalykaki, Konstantinos Koutsoukos, Georgios Kesis, Ioannis Boukovinas, Anastasios L Boutis, Pavlos Papakotoulas, Dimitrios C Ziogas, Sofia Karageorgopoulou, Stylianos Giassas, Evangelos Lianos, Natalia Chatzifoti, Fotini Papageorgiou, Zacharenia Saridaki, Journal of Clinical Oncology Volume 42, Number 16_suppl https://doi.org/10.1200/JCO.2024.42.16_suppl.3146
20.	Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer, Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsaousis, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, Florentia Fostira, George Fountzilas, Michalis Lontos, Cancers 15(23), 5525
21.	Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of

	genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). , Michael Lontos, Eleni Timotheadou, Emmanouil S Saloustros, Anna Koumarianou, Ilias Athanasiadis, Sofia Karageorgopoulou, Pavlos Papakotoulas, Ioannis Syrios, Georgios Kesis, Christos Papadimitriou, Eirini Biziota, Maria Skondra, Stylianos Giassas, Eleftherios Kampletsas, Stavros Peroukidis, Christos Christodoulou, Fotini Papageorgiou, Ioannis Boukovinas, Zacharenia Saridaki, Journal of Clinical Oncology 40 (16_suppl), e18520-e18520
22.	Abstract P5-13-01: Comprehensive tumor analysis by NGS in metastatic breast cancer patients, Eirini Papadopoulou, Nikolaos Tsoulos, Vasiliki Metaxa-Mariatou, Aikaterini Tsantikidi, Georgios Kapetsis, Chrysiida Florou-Chatzigiannidou, Sonia Maravelaki, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Tsaousis, Nikolaos Touroutoglou, Dimitrios Trafalis, Ioannis Boukovinas, Ioannis Varthalitis, Zacharenia Saridaki, Charalampos Zoublios, Eleni Galani, George Papatsibas, Christos Papadimitriou, Tania Zlatintsi, Polixenia Iorga, Bülent Orhan, Sualp Tansan, Tahsin Özatlı, George Nasioulas, Cancer Research 82 (4_Supplement), P5-13-01-P5-13-01
23.	Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVER study): a prospective cohort study of the Hellenic Cooperative Oncology Group, Helena Linardou, Nikolaos Spanakis, Georgia-Angeliki Koliou, Athina Christopoulou, Sofia Karageorgopoulou, Nephely Alevra, Anastasios Vagionas, Nikolaos Tsoukalas, Stavroula Sgourou, Elena Fountzilas, Joseph Sgouros, Evangelia Razis, Dimitra Chatzokou, Sofia Lampaki, Zacharenia Saridaki, Giannis Mountzios, George Saroglou, George Fountzilas, Cancers 13 (18), 4621
24.	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrris, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254
25.	Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma, Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrris, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou, Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas, Philippos C Patsalis, Cancers 13 (2), 198

26.	Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, ESMO open 6 (6), 100306
27.	P75. 04 advanced lung cancer inflammation index (ALI), neutrophil-to-lymphocyte ratio (NLR), and PD-(L) 1 inhibitor efficacy in NSCLC, G Mountzios, E Samantas, K Senghas, E Zervas, J Krisam, K Samitas, F Bozorgmehr, J Kuon, S Agelaki, S Baka, I Athanasiadis, L Gaissmaier, M Elshiaty, L Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, K Kriegsmann, P Kosmidis, R El Shafie, M Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C Heussel, F Herth, H Winter, C Emmanouilidis, G Oikonomopoulos, M Meister, T Muley, H Bischoff, Z Saridaki, E Razis, E Perdikouri, A Stenzinger, I Boukovinas, M Reck, K Syrigos, M Thomas, P Christopoulos, Journal of Thoracic Oncology 16 (3), S573-S574
28.	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group, Elena Fountzilas, Georgia-Angeliki Koliou, Athanassios Vozikis, Vassiliki Rapti, Achilleas Nikolakopoulos, Anastasios Boutis, Athina Christopoulou, Ioannis Kontogiorgos, Sofia Karageorgopoulou, Efthalia Lalla, Dimitrios Tryfonopoulos, Ioannis Boukovinas, Cleopatra Rapti, Adamantia Nikolaidi, Sofia Karteri, Evangelia Moirogiorgou, Ioannis Binas, Davide Mauri, Gerasimos Aravantinos, Flora Zagouri, Zacharenia Saridaki, Amanda Psyrri, Dimitrios Bafaloukos, Anna Koumarianou, Helena Linardou, Giannis Mountzios, Evangelia Razis, George Fountzilas, Georgios Koumakis, ESMO open 5 (4), e000774
29.	Association of notch and hedgehog pathway activation with prognosis in early-stage colorectal cancer, Grigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, Kyriaki Manousou, Georgia-Angeliki Koliou, Ioannis Kostopoulos, Vassiliki Kotoula, Thomas Makatsoris, Helen P Kourea, Georgia Raptou, Sofia Chrisafi, Epaminontas Samantas, Kleo Papaparaskeva, Elissavet Pazarli, Pavlos Papakostas, Georgia Kafiri, Davide Mauri, Alexandra Papoudou-Bai, Christos Christodoulou, Kalliopi Petraki, Nikolaos Dombros, Dimitrios Pectasides, George Fountzilas, Anticancer Research 39 (4), 2129-2138
30.	PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer, M Sfakianaki, C Papadaki, M Tzardi, M Trypaki, S Manoloukou, I Messaritakis, Z Saridaki, D Mavroudis, V Georgoulas, J Souglakos, Annals of Oncology 30, iv21-iv22
31.	334P - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting, E Fountzilas, G-A Koliou, V Rapti, A Nikolakopoulos, A Christopoulou, E Moirogiorgou, I Binas, G Aravantinos, L Kostadima, A Nikolaidi, S Karteri, F Zagouri, Z Saridaki, A Molfeta, P Oikonomopoulou, D Tryfonopoulos, G Koumakis, G Fountzilas, E Razis, Annals of Oncology 30, v118
32.	Screening of colorectal cancer (CRC) patients for lynch syndrome (LS) emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Zacharenia

	Saridaki, Emmanouil S Saloustros, Nikolaos Tsoukalas, Thomas Makatsoris, Georgios Lypas, Haralabos Kalofonos, Athina Christopoulou, Iliada Bompoulaki, Ioannis Souglakos, Evangelos Voulgaris, Athanasios Karampeazis, Christos Papandreou, Athanasios Anagnostopoulos, Eleni P Galani, Konstantinos Ballasis, Flora Zagouri, Georgios Rizos, Athanasios Athanasiadis, Ioannis I Varthalitis, Ioannis Boukovinas, Journal of Clinical Oncology 37 (15_suppl), e13141-e13141
33.	Colchicum genus in the writings of ancient Greek and Byzantine physicians, Gregory Tsoucalas, Theodoros Papaioannou, George Panayiotakopoulos, Zenia Saridaki, Dimitrios A Vrachatis, Marianna Karamanou, Current pharmaceutical design 24 (6), 648-653
34.	One in four women with high-grade serous ovarian cancer carries a loss-of-function BRCA1 & BRCA2 germline allele, F Fostira, MS Papamentzelopoulou, E Saloustros, P Apostolou, V Mollaki, A Vagena, K Tsakiri, I Athanasiadis, E Timotheadou, G Lypas, Z Saridaki, I Boukovinas, G Aravantinos, M Lontos, C Papadimitriou, I Varthalitis, D Yannoukakos, A Athanasiadis, I Konstantopoulou, EUROPEAN JOURNAL OF HUMAN GENETICS 26, 530-531
35.	Hellenic Alliance for Metastatic Breast Cancer: A Platform of Support, a Platform for Life, A Tarampikou, Z Saridaki, S Kolokotroni, A Christopoulou, S Agelaki, E Galani, A Psyrris, A Nikolaidi, H Linardou, Journal of Global Oncology, 165s-165s
36.	Access to Genetic Testing Impacts Oncologists' Decisions on Ovarian Cancer Personalized Treatment: Lessons Learned From a National Program in Greece, I Boukovinas, G Lypas, M Lontos, C Andreadis, C Papandreou, P Papakotoulas, G Aravantinos, E Bournakis, S Karageorgopoulou, E Maragkouli, N Ziras, S Kakolyris, I Athanasiadis, E Linardou, A Koumariannou, C Kalofonos, G Pentheroudakis, I Korantzis, C Christodoulou, P Kosmidis, D Daliani, A Ardavanis, G Koumakis, I Bankousli, P Makrantonakis, G Kesisis, M Nikolaou, E Diamantidou, N Tsoukalas, I Xanthakis, A Fassas, V Barbounis, A Anagnostopoulos, A Polyzos, A Athanasiadis, I Syrios, S Peroukidis, I Mpompoulaki, S Baka, N Androulakis, V Georgoulis, C Emmanouilidis, D Mavroudis, I Sgouros, C Stathopoulos, O Katopodi, I Varthalitis, P Sarikaki, E Saloustros, Z Saridaki, Journal of Global Oncology, 74s-74s
37.	Frequent germline BRCA1/2 mutations in women with ovarian cancer and the need for insurance coverage of genetic testing: A Hellenic Society of Medical Oncology (HeSMO) national program. , Georgios Lypas, Zacharenia Saridaki, Emmanouil S Saloustros, Michael Lontos, Evangelos Bournakis, Christos Papandreou, Evangelos Lianos, Haralabos Kalofonos, Elena Maragouli, Gerasimos Aravantinos, Nikolaos Xenidis, Charalampos Andreadis, Eleni Stergiou, Alexandros Bokas, Cedric Gouedard, George Nasioulas, Fotini Papageorgiou, Athanasios Athanasiadis, Ioannis Varthalitis, Ioannis Boukovinas, Journal of Clinical Oncology 36 (15_suppl), e13525-e13525
38.	Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity, Pratyaksha Wirapati, Valentina Pomella, Ben Vandenbosch, Peter Kerr, Evaristo Maiello, Mark Jeffery Grahame, Razvan-Ovidiu D Curca, Meinolf Karthaus, John A Bridgewater, Anca C Mihailov, Igor Kiss, Sandra Merino, James McKendrick Joseph, Zacharenia Saridaki, Xavier JA Sagaert, Sabine Tejpar, Annals of Oncology 28, iii151-iii152
39.	Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial

	ovarian cancer who received platinum-taxane first-line therapy, S Pontikakis, C Papadaki, M Tzardi, M Trypaki, M Sfakianaki, F Koinis, E Lagoudaki, L Giannikaki, A Kalykaki, E Kontopodis, Z Saridaki, N Malamos, V Georgoulas, J Souglakos, The pharmacogenomics journal 17 (6), 506-514
40.	André Levret (1703-1780): the eminent obstetrician of the 18th century and his innovative approach to the treatment of uterine polyps, Marianna Karamanou, Christos Iavazzo, Zenia Saridaki, Konstantinos Gritzalis, George Androutsos, Balkan Union of Oncology. Journal 22, 562-565
41.	New treatments in Oncology: Clinical practice regarding the management of Adverse Events (AEs). Results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO), M Lontos, F Koinis, G Chatsidis, K Kamposioras, G Papaxoinis, M Nikolaou, K Tsigaridas, E Voulgaris, E Pantavou, G Aravantinos, A Ardavanis, I Boukovinas, E Galani, S Angelaki, G Mountzios, Z Saridaki, I Varthalitis, N Tsoukalas, Annals of Oncology 28, v517
42.	Reduced expression of SMAD4 is associated with poor survival in colon cancer, Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas Alexander McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fredrik T Bosman, Roberto Fiocca, Clinical Cancer Research 22 (12), 3037-3047
43.	P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG), John Souglakos, Zacharenia Saridaki, N Gouges, Alexandra Voutsina, Maria Tzardi, Aristeia Kalikaki, Maria Sfakianaki, Athanasios Athanasiadis, Evangelos Xynos, Ioannis Boukovinas, Annals of Oncology 27, ii9
44.	Career Development and Oncology Education in Europe: Final results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)., Nikolaos Tsoukalas, Eleni Aravantinou-Fatorou, Konstantinos Kamposioras, Athanasios Korogiannos, Vasileios Papadopoulos, Ioannis Kostakis, George Lazaridis, Michail Nikolaou, Evangelos Voulgaris, Michael Lontos, Kostas Tsigaridas, Evangelos Bournakis, Athanasios Athanasiadis, Gerasimos Aravantinos, Alexandros Ardavanis, Ioannis Boukovinas, Eleni P Galani, Giannis Mountzios, Zacharenia Saridaki, Ioannis Varthalitis, Journal of Clinical Oncology 34 (15_suppl), e18202-e18202
45.	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, D Klingbiel, Z Saridaki, AD Roth, FT Bosman, M Delorenzi, Sabine Tejpar, Annals of oncology 26(1), 126-132
46.	KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?, Z Saridaki, X Saegart, Veerle De Vriendt, D Hatzidaki, Sander Palmans, Linde De Smedt, Gert De Hertogh, Sabine Tejpar, British Journal of Cancer 113 (6), 914-920
47.	René-Théophile-Hyacinthe Laennec (1781-1826) and the description of metastatic pulmonary melanoma, M Karamanou, AJ Stratigos, Z Saridaki, G Tsoucalas, G Androutsos, J BUON 20 (1), 354-6
48.	Avenzoar's (1091-1162) clinical description of cancer, M Karamanou, G Tsoucalas, Z Saridaki, C Iavazzo, G Androutsos, J BUON 20 (4), 1171-4

49.	How to identify the right patients for the right treatment in metastatic colorectal cancer (mCRC), Z Saridaki, N Asimakopoulou, I Boukovinas, J Souglakos, Current Colorectal Cancer Reports 11, 151-159
50.	Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma, Zacharenia Saridaki, Georgia Lambrodinou, Stefanos Kachris, Paris Makrantonakis, Ioannis Boukovinas, Aris Polyzos, Athanasios Anagnostopoulos, Athanasios Athanasiadis, Dimitris Stoltidis, Vassilis Georgoulas, John Souglakos, American Journal of Clinical Oncology 38 (1), 17-22
51.	Prognostic and predictive significance of MSI in stages II/III colon cancer, Z Saridaki, J Souglakos, V Georgoulas, Z Saridaki, J Souglakos, V Georgoulas, World Journal of Gastroenterology: WJG 20 (22), 6809
52.	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy, Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piesseaux, Sabine Tejpar, Clinical Cancer Research 20 (17), 4499-4510
53.	ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples Expressão ERCC1 Correlacionada com EGFR e Variáveis Clinicopatológicas em Doentes com Carcinoma Pulmonar de Não Pequenas Células. Um estudo imunocitoquímico em amostras biópsias aspirativas por agulha fina, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, Z Saridaki, M Tzardi, Revista Portuguesa de Pneumologia (English Edition) 20(4), 200-207
54.	Cost-effectiveness analysis of panitumumab+ mFOLFOX over bevacizumab+ mFOLFOX as a first-line treatment for metastatic colorectal cancer patients with wild-type RAS in Greece, G Kourlaba, I Boukovinas, Z Saridaki, V Papagiannopoulou, G Tritaki, N Maniadas, Value in Health 17 (7), A633
55.	Women 4 Oncology in Greece: Exploring Common Challenges-Survey of the Hellenic Society of Medical Oncology Among Women Oncology Professionals, H Linardou, A Christopoulou, S Agelaki, E Galani, Z Saridaki, A Psyrris, A Athanasiadis, Annals of Oncology 25, v1
56.	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome, Zacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, Chara Papadaki, Alexandra Voutsina, Aristeia Kalykaki, Ippokratis Messaritakis, Kyriakos Mpananis, Dimitris Mavroudis, Efstathios Stathopoulos, Vassilis Georgoulas, John Souglakos, PLoS one 8 (12), e84604
57.	The eminent dermatologist Moriz Kaposi (1837-1902) and the first description of idiopathic multiple pigmented sarcoma of the skin, M Karamanou, C Antoniou, AJ Stratigos, Z Saridaki, G Androutsos, J buon 18 (4), 1101-5
58.	Genetic alterations in colorectal cancer in older patients, Z Saridaki, J Souglakos, Management of Colorectal Cancers in Older People, Management of Colorectal Cancers in Older People, 2013, p. 9-20

59.	A retrospective analysis regarding the parameters, which influence the administration of adjuvant chemotherapy in for elderly patients (>70years) with stage II or III colon cancer in the daily clinical practice, N Asimakopoulou, P Papakonstantinou, J Souglakos, A Karampeazis, Z Saridaki, P Koinis, A Matikas, C Nikolaou, V Georgoulas, L Vamvakas, Journal of geriatric oncology 4, S40-S41
60.	Pkm2 Expression Could Predict Resistance to Oxaliplatin Combination Chemotherapy in Patients with Stage Ii/Iii or Metastatic Colorectal Cancer, G Mountzios, E Samantas, K Senghas, E Zervas, J Krisam, K Samitas, F Bozorgmehr, J Kuon, S Agelaki, S Baka, I Athanasiadis, L Gaissmaier, M Elshiaty, L Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, K Kriegsmann, P Kosmidis, R El Shafie, M Kriegsmann, A Psyrri, C Andreadis, E Fountzilas, C Heussel, F Herth, H Winter, C Emmanouilidis, G Oikonomopoulos, M Meister, T Muley, H Bischoff, Z Saridaki, E Razis, E Perdikouri, A Stenzinger, I Boukovinas, M Reck, K Syrigos, M Thomas, P Christopoulos, Annals of Oncology 24, iv115
61.	Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer, Z Saridaki, J Souglakos, Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance, Springer New York
62.	The great surgeon Jean-Louis Faure (1863-1944) and his contribution in the treatment of uterine cancer, M Kamanou, Z Saridaki, M Piagkou, K Laios, G Androutsos, J BUON 18 (1), 296-298
63.	Aretaeus of Cappadocia and the first description of diabetes, K Laios, M Kamanou, Z Saridaki, G Androutsos, Hormones 11, 109-113
64.	A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial, Z Saridaki, N Androulakis, N Vardakis, L Vamvakas, E Kabouraki, K Kalbakis, D Hatzidaki, A Voutsina, D Mavroudis, V Georgoulas, J Souglakos, British journal of cancer 107 (12), 1932-1937
65.	A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer, Zacharenia Saridaki, Nikolaos Malamos, Panagiotis Kourakos, Aristides Polyzos, Alexandros Ardavanis, Nikolaos Androulakis, Kostas Kalbakis, Lambros Vamvakas, Vassilis Georgoulas, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 69, 35-42
66.	Cytopathologic interpretation of ascites due to malignancy, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, A Papathanasiou, Z Saridaki, EN Stathopoulos, M Tzardi, J buon 17 (3), 446-51
67.	Clinical implications and quality assurance of molecular testing for EGFR-targeting agents in colorectal cancer, Loredana Vecchione, Zenia Saridaki, Sabine Tejpar, Current Colorectal Cancer Reports 8, 42-50
68.	Gastrointestinal tumors, colorectal, D Arnold, HJ Schmoll, J Riera-Knorrenschild, F Mayer, H Kroening, W Scheithauer, D Nitsche, M Tschaika, M Schmidt, B Wittig, T Price, K Wilson, RJ Simes, D Yip, CS Karapetis, NC Tebbutt, V GebSKI, M Fournier, DR Ferry, D Ransom, R Salazar, E Mini, G Folprecht, F Subtil, J van Laethem, J Thaler, JA Bridgewater, E Van Cutsem, C Lepage, J Taieb, S Venderbosch, T De Haan, DAM Heideman, TS Maughan, CG Smith, P Quirke, SD Richman, ID Nagtegaal, CJA Punt, M Koopman, T Bachleitner-Hofmann, I Simon, R Salazar, J Tabernero, R Rosenberg, J van der Akker, Y Li, B Chan, G Lanza, A Glas, MJ

	O'Connell, M Lee, M Lopatin, G Yothers, KM Clark-Langone, C Millward, S Paik, S Sharif, S Shak, N Wolmark, P Li, G Chen, P Laurent-Puig, G Manceau, J Bachet, B Chibaudel, F Liebaert, O Bouché, F Penault-Llorca, MD Diebold, T André, S Imbeaud, V Heinemann, R Laubender, DP Modest, A Jung, L Fischer von Weikersthal, U Vehling-Kaiser, C Giessen, T Kirchner, U Mansmann, S Stintzing, A Custodio, J Moreno, J Aparicio, J Gallego Plazas, C Fernández Martos, J Maurel, D Ramos, P Cejas, R Madero, J Feliu, AAL Pereira, JFM Rego, PM Hoff, A Sasse, RP Riechelmann, E Mitry, L Venat-Bouvet, J Phelip, E Maillard, J Jouve, X Adhoute, D Gargot, M Gasmi, L Bedenne, T Aparicio, RS Midgley, S Love, V Potter, E Segelov, DR Ferry, A Weaver, C Scudder, P Julier, S Grumett, DJ Kerr, S Ahmed, RK Shahid, A Leis, K Haider, P Pahwa, T Price, J Hardingham, C Lee, A Townsend, J Wrin, K Wilson, A Weickhardt, RJ Simes, C Munroe, N Tebbutt, IB Tan, T Seah, SL Koo, S Choo, CK Tham, D Chong, I López Calderero, AC Moya, AA Gonzalez, AC Carranza, MC Conde, S Molina-Pinelo, MDP Herrera, MLL Miron, PE Garcia, R Garcia-Carbonero, F Cappuzzo, A Sacconi, Annals of Oncology-English Edition 23 (9), ix178
69.	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (MCRC) In Daily Clinical Practice: Correlations with Clinical Characteristics, Prognostic and Predictive Values, Z Saridaki, M Tzardi, M Sfakianaki, C Papadaki, K Mpananis, E Tsakalaki, M Trypaki, I Messaritakis, V Georgoulas, J Souglakos, Annals of Oncology 23, ix213
70.	PKM2 mRNA expression to predict disease recurrence in patients with stage II or III colon cancer treated with oxaliplatin in combination with fluoropyrimidines., C Papadaki, Z Saridaki, M Tzardi, M Sfakianaki, G Sfakiotaki, M Trypaki, I Messaritakis, D Mavroudis, V Georgoulas, I Souglakos, Journal of Clinical Oncology 30 (4_suppl), 468-468
71.	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients, Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristea Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efsthios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulas, John Souglakos, PloS one 6 (1), e15980
72.	Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle, S Tejpar, Z Saridaki, M Delorenzi, F Bosman, AD Roth, Journal of the National Cancer Institute 103 (11), 841-844
73.	Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer, Nikolaos Vardakis, Ippokratis Messaritakis, Chara Papadaki, Georgios Agoglossakis, Maria Sfakianaki, Zacharenia Saridaki, Stella Apostolaki, Ioannis Koutroubakis, Maria Perraki, Dora Hatzidaki, Dimitris Mavroudis, Vassilis Georgoulas, John Souglakos, Clinical Cancer Research 17 (1), 165-173
74.	Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer, E Saloustros, K Kalbakis, N Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulas, D Mavroudis, J BUON 16 (2), 215-8

75.	Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study, Athanasios G Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvakas, Nikolaos Vardakis, Zacharenia Saridaki, George Samonis, Stylianos Giassas, Vassilis Georgoulas, Sophia Agelaki, Clinical Lung Cancer 12 (2), 100-105
76.	PHASE II TRIAL OF LOW-DOSE METRONOMIC ORAL VINOELBINE COMBINED WITH BEVACIZUMAB IN PATIENTS WITH PRETREATED, ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC), E Kontopodis, Z Saridaki, N Kentepozidis, S Giassas, A Polyzos, I Bobolaki, Ch Christophyllakis, S Patramani, M Rovithi, V Georgoulas, S Agelaki, JOURNAL OF THORACIC ONCOLOGY 6 (6), S1244-S1245
77.	PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC)., C Papadaki, Z Saridaki, M Tzardi, M Sfakianaki, G Sfakiotaki, M Trypaki, I Messaritakis, D Mavroudis, V Georgoulas, I Sougklakos, Journal of Clinical Oncology 29 (4_suppl), 434-434
78.	Folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus chemoradiation (CRT) with 5-fluorouracil (5FU) as adjuvant treatment for patients with operable gastric cancer (OGC): A feasibility study with pharmacogenetic analysis. A Athanasiadis, I Boukovinas, M Sfakianaki, Z Saridaki, C Papadaki, M Tzardi, NE Androulakis, A Polyzos, V Georgoulas, I Sougklakos, Journal of Clinical Oncology 29 (4_suppl), 44-44
79.	Impact of KRAS, BRAF, and PIK3CA mutations, PTEN, AREG, and EREG expression, and skin rash in metastatic colorectal cancer patients treated with cetuximab-containing salvage treatment., Z Saridaki, M Tzardi, C Papadaki, M Sfakianaki, F Pega, A Kalikaki, E Tsakalaki, D Mavroudis, V Georgoulas, I Sougklakos, Journal of Clinical Oncology 29 (4_suppl), 445-445
80.	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer, Panayiotis A Theodoropoulos, Hara Polioudaki, Sofia Agelaki, Galatea Kallergi, Zacharenia Saridaki, Dimitris Mavroudis, Vassilis Georgoulas, Cancer letters 288 (1), 99-106
81.	BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome, Z Saridaki, D Papadatos-Pastos, M Tzardi, D Mavroudis, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulas, J Souglakos, British journal of cancer 102 (12), 1762-1768
82.	Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer, Zacharenia Saridaki, Vassilis Georgoulas, John Souglakos, World journal of gastroenterology: WJG 16 (10), 1177
83.	A retrospective analysis of non-platinum-based first-and second-line chemotherapy in patients with advanced non-small cell lung cancer, Athanasios Kotsakis, Dora Hatzidaki, Lambros Vamvakas, Nikolaos Vardakis, Antonia Kalykaki, Vasiliki Bozionelou, Nikolaos Androulakis, Kostas Kalbakis, Zacharenia Saridaki, Vassilis Georgoulas, Sophia Agelaki, Anticancer research 30 (10), 4335-4342

84.	Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study., ES Saloustros, K Kalbakis, NK Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulas, D Mavroudis, Journal of Clinical Oncology 28 (15_suppl), 1133-1133
85.	PAZOPANIB: a second generation antiangiogenic multitargeted tyrosine kinase inhibitor, N Karaxaliou, Z Saridaki, ForuM of CliniCAI onColoGY, 33-39
86.	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, J Souglakos, J Philips, R Wang, S Marwah, M Silver, M Tzardi, J Silver, S Ogino, S Hooshmand, E Kwak, E Freed, JA Meyerhardt, Z Saridaki, V Georgoulas, D Finkelstein, CS Fuchs, MH Kulke, RA Shivdasani, British journal of cancer 101 (3), 465-472
87.	Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study, Charalambos Kouroussis, Lambros Vamvakas, Nikolaos Vardakis, Athanasios Kotsakis, Antonia Kalykaki, Kostas Kalbakis, Zacharenia Saridaki, Nikolaos Kentepozidis, Stelios Giassas, Vassilis Georgoulas, Oncology 76 (2), 112-117
88.	A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors, Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Marios Marselos, Vassilis Georgoulas, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 65, 121-128
89.	1016 Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy, Z Saridaki, M Tzardi, D Papadatos-Patsos, E Kampouraki, E Zois, E Stathopoulos, V Georgoulas, D Mavroudis, J Souglakos, EJC Supplements 2 (7), 91-92
90.	Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial, Ioannis Gioulbasanis, Zacharenia Saridaki, Antonia Kalykaki, Lambros Vamvakas, Kostas Kalbakis, Michail Ignatiadis, Kyriakos Amarantidis, Stylianos Kakolyris, Vassilis Georgoulas, Dimitris Mavroudis, Anticancer research 28 (5B), 3019-3025
91.	The relationship between measures of nutritional status and Comprehensive Geriatric Assessment, Z Giannousi, L Vamvakas, E Saloustros, A Karampeazis, I Gioulbasanis, G Sfakiotaki, E Kontopodis, Z Saridaki, V Bozionelou, V Georgoulas, Critical Reviews in Oncology/Hematology, S33
92.	A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors, A Kalykaki, L Vamvakas, Sofia Agelaki, K Kalbakis, N Vardakis, G Sfakiotaki, Michail Ignatiadis, Z Saridaki, A Karampeazis, D Mavroudis, V Georgoulas, Oncology 71 (3-4), 197-203
93.	A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors, Zacharenia Saridaki, Vasiliki Bozionelou, Nikolaos Kentepozidis, Athanasios Kotsakis, Nikolaos Vardakis, Antonia Kalykaki, Ioannis Gioulbasanis, Athanasios Karampeazis, Lambros Vamvakas, Vassilis Georgoulas, Dimitris Mavroudis, Oncology 72 (1-2), 45-50

94.	Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract, I Gkioulbasanis, J Souglakos, N Vardakis, A Kotsakis, Z Saridaki, N Kentepozidis, A Polyzos, S Giassas, Michail Ignatiadis, V Bozionelou, C Christophylakis, Vassilis Georgoulas, JOURNAL-BALKAN UNION OF ONCOLOGY 12 (2), 197
95.	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status, John Souglakos, Lambros Vamvakas, Stella Apostolaki, Maria Perraki, Zacharenia Saridaki, Irine Kazakou, Athanasios Pallis, Charalambos Kouroussis, Nikos Androulakis, Kostas Kalbakis, Georgia Millaki, Dimitris Mavroudis, Vassilis Georgoulas, Breast Cancer Research 8 (4), 1-8
96.	Correlation of microsatellite instability (MSI) status with clinical parameters and treatment outcomes for patients with metastatic colorectal cancer (MCC) treated with a triplet combination with irinotecan (CPT-11), oxaliplatin (L-OHP) plus bolus and infusional 5FU/leucovorin (degramont regimen)-FOLFOXIRI, I Souglakos, D Papadatos-Pastos, M Tzardi, Z Saridaki, N Zois, M Peraki, D Mavroudis, V Georgoulas, ANNALS OF ONCOLOGY 17, 44-44
97.	Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors, Ch Kouroussis, N Androulakis, L Vamvakas, A Kalykaki, S Spiridonakou, N Kentepozidis, Z Saridaki, El Xiropoulou, V Georgoulas, Oncology 69 (3), 202-207
98.	Idiopathic CD4+ T lymphocytopenia disclosed by recurrent cryptococcal meningitis. First case report from Greece, Diamantis P Kofteridis, Zacharenia Saridaki, Ireni Kazakou, Silvia Lazaridou, Dimitris Alegakis, Georgia Milaki, Achilleas Gikas, International Journal of Infectious Diseases 9 (6), 347-348
99.	A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors, John Souglakos, Stylianos Kakolyris, Nikolaos Vardakis, Nikolaos Androulakis, Dimitrios Mavroudis, Lambos Vamvakas, Charalambos Kouroussis, Sophia Agelaki, Zacharenia Saridaki, Vassilis Georgoulas, Cancer investigation 23 (6), 505-510
100	Endothelial p21WAF1/Cip1 cell cycle inhibitor is down-regulated in breast cancer, T Vrekoussis, EN Stathopoulos, M Kafousi, Z Saridaki, E Sanidas, O Zoras, Anticancer research 25 (4), 2743-2748
101	First line chemotherapy with docetaxel plus gemcitabine in elderly or poor performance status patients with advanced non-small cell lung cancer: the experience of the Hellenic Oncology Research Group (HORG)." M Ignatiadis, K Kalbakis, N Vardakis, S Giassas, G Sfakiotaki, Z Saridaki, V Bozionelou, J Gioulbasakis, A Pallis, V Georgoulas, EJC SUPPLEMENTS 3 (2), 332-332
102	First line treatment with docetaxel and cisplatin in non-small cell lung cancer patients: A retrospective analysis, N Kentepozidis, S Agelaki, L Vamvakas, A Kotsakis, Z Saridaki, J Gioulbasakis, A Kalykaki, M Ignatiadis, G Sfakiotaki, D Mavroudis, LUNG CANCER 49, S251-S251
103	Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after combination chemotherapy including oxaliplatin, irinotecan (CPT-11), and 5-fluorouracil (5-FU) or capecitabine, J Souglakos, N Androulakis, A Kalykaki, Z Saridaki, N Vardakis, K

	Kalbakis, S Agelaki, L Vamvakas, N Kentepozidis, S Giassas, D Mavroudis, V Georgoulas, ANNALS OF ONCOLOGY 16, 41-41
104	P-509 First line treatment with docetaxel and cisplatin in non-small cell lung cancer patients: A retrospective analysis, N Kentepozidis, S Agelaki, L Vamvakas, A Kotsakis, Z Saridaki, J Gioulbasakis, A Kalykaki, M Ignatiadis, G Sfakiotaki, D Mavroudis, Lung Cancer, S250-S251
105	Intestinal ischemia as the first manifestation of vasculitis, Freda H Passam, Ioannis D Diamantis, Garyfalia Perisinaki, Zenia Saridaki, Herakles Kritikos, Dimitrios Georgopoulos, Dimitrios T Boumpas, Seminars in arthritis and rheumatism 34 (1), 431-441
106	A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC), D Mavroudis, E Efstathiou, A Polyzos, A Athanasiadis, G Milaki, E Kastritis, A Kalykaki, Z Saridaki, A Dimopoulos, V Georgoulas, Journal of Clinical Oncology 22 (14_suppl), 5020-5020
107	Increase incidence of central nervous system (CNS) involvement for patients with breast cancer (BC) treated with Taxanes based chemotherapy, J Souglakos, L Vamvakas, Z Saridaki, I Kazakou, A Pallis, K Kalbakis, A Kalikaki, V Biozionelou, V Georgoulas, ANNALS OF ONCOLOGY 15, 30-30
108	A non-comparative study of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with cisplatin-sensitive and-refractory advanced ovarian cancer, D Mavroudis, E Efstathiou, G Aravantinos, M Karina, A Polyzos, E Kastritis, A Kalikaki, Z Saridaki, MA Dimopoulos, V Georgoulas, ANNALS OF ONCOLOGY 15, 130-130
109	Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, O Zoras, DA Spandidos, British Journal of Dermatology 148 (4), 638-648
110	First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer, G Fiorentini, D Tsetis, P Bernardeschi, C Varveris, S Rossi, A Kalogeraki, E Athanasakis, P Dentico, P Kanellos, M Biancalani, S Almarashdah, G Zacharioudakis, Z Saridaki, G Chalkiadakis, E Xynos, O Zoras, Anticancer research 23 (5), 4339-4346
111	Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction, DP Kofteridis, S Karabekios, JG Panagiotides, J Bizakis, D Kyrmizakis, Z Saridaki, A Gikas, Journal of chemotherapy 15 (3), 282-286
112	Paclitaxel, carboplatin and gefitinib ('Iressa', ZD1839) as first-line chemotherapy in patients with advanced breast cancer: a phase II study, G Founizilas, D Pectasides, DV Skarlos, H Kalofonos, C Papadimitriou, H Linardou, A Kalogera-Fountzila, Z Saridaki, E Briassoulis, S Papadopoulos, S Lambropoulos, P Kosmidis, E Razis, H Gogas, BREAST CANCER RESEARCH AND TREATMENT 82, S85-S85 / Conference: 26th Annual San Antonio Breast Cancer Symposium
113	Mutations of p16INK4a and p14ARF tumor suppressor genes in SCC of the skin and lack of mutation in BCC, UJ Zoras, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, DA Spandidos, ANNALS OF SURGICAL ONCOLOGY 10 (1), S78-S79

114	Surgical repair of incisional ventral hernias: tension-free technique using prosthetic materials (expanded polytetrafluoroethylene Gore-Tex Dual Mesh), Emmanuel Chrysos, Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Dimitra Dimitriadou, Vasilios Koutsoumpas, George Chalkiadakis, Evangelos Xynos, Odysseas Zoras, The American Surgeon 66 (7), 679-682
115	High frequency of loss of heterozygosity on chromosome region 9p21–p22 but lack of p16INK4a/p19ARF mutations in Greek patients with basal cell carcinoma of the skin, Zacharenia Saridaki, George Sourvinos, Demetrios A Spandidos, Elma Koumantaki, Triantafillos Liloglou, Othon Papadopoulos, Odysseas Zoras, Journal of investigative dermatology 115 (4), 719-725
116	Surgical repair of inguinal hernia: tension free technique with prosthetic materials (Gore-Tex Mycro Mesh expanded polytetrafluoroethylene), Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Emmanuel Chrysos, George Prokopakis, Nickolaos Vrahasotakis, Evangelos Xynos, George Chalkiadakis, Odysseas Zoras, The American Surgeon 66 (8), 728-731

Δημοσιεύσεις, ανακοινώσεις, ePosters που έγιναν από την ΕΟΠΕ κατά τη διάρκεια της Προεδρίας της στην Εταιρεία (2021 – 2025)

1.	Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid tumors. Journal of Chemotherapy, Pappas G., Tsoukalas N., Boutis A., Saloustros E., Gazouli I., Gkoura S., Zakopoulou R., Aidarinis C., Boukovinas I., Koumarianou A., Kokkali S., Gkoumas G., Vlachostergios P.J., Assi A., Karampeazis A., Nikolaidi A., Fountzilas E., Chatzifoti N., Saridaki Z. (2025) under review (2nd round).
2.	Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study, E Fountzilas, S Karageorgopoulou, G Karakatsoulis, D Tryfonopoulos, K Papazisis, A Koutras, A Koumarianou, G Zafeiri, E Biziota, A Nikolaidi, I Boukovinas, E Vrana, D Mauri, E Aravantinou-Fatorou, E Razis, E Vorrias, Z Saridaki, D Bafaloukos, A Christopoulou, A Boutis, N Tsoukalas, S Stamatopoulou, N Spathas, M Theochari, F Zagouri, A Psyri, G Fountzilas, E Lalla, ESMO Real World Data and Digital Oncology, 7, 1095, https://doi.org/10.1016/j.esmorw.2024.100095
3.	Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece, S Manolakou, N Tsoukalas, E Saloustros, T Makatsoris, I Boukovinas, A Christopoulou, A Karampeazis, I Bompoulaki, I-I Varthalitis, E Voulgaris, K Ballasis, A Boutis, E Galani, C Kalofonos, A Koumarianou, C Kourousis, P Papakotoulas, C Papandreou, E-I Perdikouri, A Andreadou, I Athanasiadis, F-I Dimitrakopoulos, C Emmanouilidis, E Kampletsas, O Katopodi, P Kosmidis, K Koutsoukos, E Lianos, P Makrantonakis, E Ntouvelis, C Panopoulos, V Papadopoulos, G Pentheroudakis, E Samantas, I Stoupis, G Tsironis, N Chatzifoti, I Souglakos, Z Saridaki, ESMO

	Gastrointestinal Oncology, 8, 100153, https://doi.org/10.1016/j.esmogo.2025.100153
4.	Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer, E Fountzilas, J Souglakos, J Alafis, K Dadouli, A Koumarianou, N Tsoukalas, A Nikolaidi, D Mauri, M Karagianni, A Anna, A Psyrri, G Rigakos, A Avgerinos, M Theochari, D Pectasides, G Oikonomopoulos, A Vagionas, P Papakostas, A Christopoulou, G Fountzilas, Z Saridaki, ESMO Gastrointestinal Oncology 5, 100073
5.	Exploring the use of a digital platform for cancer patients to report their demographics, disease and therapy characteristics, age, and educational disparities: An early-stage feasibility study, Galiti D., Linardou H., Agelaki S., Karampeazis A., Tsoukalas N., Psyrri A., Karamouzis M., Syrigos K.N., Ardavanis A., Athanasiadis I., Arvanitou E., Sgourou S., Mala A., Vallilas Ch., Boukovinas I. (2023). Current Oncology, 30(8), 7608-7619.
6.	CureCancer platform facilitates patients' self-data recording, treatment adherence and "distancing interventions". A feasibility and satisfaction study, Galiti D., Linardou H., Agelaki S., Karampeazis A., Tsoukalas N., Psyrri A., Karamouzis M., Syrigos K., Ardavanis A., Athanasiadis I., Arvanitou E., Sgourou S., Kouloulis V., Mala A., Vallilas Ch., Boukovinas I. (2022). Clinics of Oncology, 6(3), 1-8.
7.	Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). , Michael Lontos, Eleni Timotheadou, Emmanouil S Saloustros, Anna Koumarianou, Ilias Athanasiadis, Sofia Karageorgopoulou, Pavlos Papakotoulas, Ioannis Syrios, Georgios Kesis, Christos Papadimitriou, Eirini Bizioti, Maria Skondra, Stylianos Giassas, Eleftherios Kampletsas, Stavros Peroukidis, Christos Christodoulou, Fotini Papageorgiou, Ioannis Boukovinas, Zacharenia Saridaki, Journal of Clinical Oncology 40 (16_suppl), e18520-e18520
8.	Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, ESMO open 6 (6), 100306 Πρώτη δημοσίευση της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) στο ESMO Open

9.	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrris, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254
10.	Bridging the gap between knowledge, attitudes, and practice regarding physical activity and exercise among Greek medical oncologists. Voulgaris E., Jamurtas A.Z., Stavropoulos-Kalinoglou A., Fatouros I.G., Metsios G.S., Draganidis D., Mastorakos G., Tsimeas P., Poulios A., Saridaki Z. , Syrou N. (2026). <i>Journal of Clinical Oncology</i> , 44(16_suppl), e23141. 2026 ASCO Annual Meeting. https://doi.org/10.1200/JCO.2026.44.16_suppl.e23141
11.	The landscape of PIK3CA mutations and their prognostic impact on recurrence in HR+/HER2- breast cancer: A real-world multicenter analysis. Presentation No. 219eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025. Boutis A., Nikolaou M., Ardavanis A., Zagouri F., Koumarianou A., Timotheadou E., Tolis C., Christopoulou A., Korantzis I., Kampletsas E., Lontos M., Loga K., Kesis G., Bizioti I., Papatsimpas G., Karageorgopoulou S., Antoniadou K., Chatzifoti N., Saridaki Z. (2025). Presentation No. 219eP. ESMO Congress 2025, held in Berlin from 17–21 October 2025. Πρώτη δημοσίευση της Εταιρείας Ογκολόγων Παθολόγων Ελλάδας (ΕΟΠΕ) στο ESMO Open
12.	Empowering Primary Care Providers (PCPs) in Cancer Survivorship: Insights from the ASCO HeSMO Project ECHO in Greece. Tsoukalas N., Razis E., Boukovinas I., Lionis C., Chatzifoti N., Eaton V., Gould A., Kremzier M., Sarchet V., Schapira L., Saridaki Z. (2025). Presentation No. 3192eP. ESMO Congress 2025, to be held in Berlin from 17–21 October 2025.
13.	E1858P - efficacy and safety of thromboprophylaxis in oncology patients with Khorana score <2: Combined results from GMat and ACT4CAT studies. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Kalofonos C., Psyrris A., Kapodistrias N., Papakostas P., Samantas E., Aravantinos G., Papakotoulas P., Boukovinas I. (2024), <i>Annals of Oncology</i> , 35(Suppl 2), p.S1094.

14.	Comprehensive molecular profiling of newly diagnosed advanced, high-grade ovarian cancer: Unveiling BRCA1/2 mutations and genomic instability scores to advocate for public insurance coverage of genetic testing—Insights from the Hellenic Society of Medical Oncology (HeSMO) national program., D Bafaloukos, A Molfeta, I Gazouli, E Chatzichristou, A Bousboukea, A Tarampikou, A Giorgali, Z Saridaki, G Samonis, Journal of Clinical Oncology 42 (16_suppl), 3146-3146
15.	Safety and acceptance of nirmatrelvir/ritonavir in early SARS-CoV-2 treatment in Greek patients with solid cancer. Pappas G., Tsoukalas N., Boutis A., Saloustros E., Gazouli I., Gkoura S., Zakopoulou R., Aidarinis C., Boukovinas I., Koumarianou A., Kokkali S., Gkoumas G., Vlachostergios P., Assi A., Karampeazis A., Nikolaidi A., Fountzila E., Chatzifoti N., Saridaki Z. (2024). Journal of Clinical Oncology, 42, Number 16_suppl.
16.	439P - Testing HR+/HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Boutis A., Nikolaou M., Ardavanis A., Tolis C., Loga K., Korantzis I., Koumarianou A., Christopoulou A., Papatsimpas G., Bokas A., Pliarchopoulou K., Kampletsas E., Kesisis G., Biziota E., Psianou K., Karageorgopoulou S., Sogka E., Tsoukalas N., Chatzifoti N., Saridaki Z. (2023). Annals of Oncology, 34, S366.
17.	2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Kalofonos C., Psyrris A., Kapodistrias N., Papakostas P., Pentheroudakis G., Aravantinos G., Papakotoulas P., Boukovinas I. (2023). Annals of Oncology, 34(Suppl 2), p.S1104.
18.	<i>Testing of newly diagnosed advanced high-grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). Lontos M., Timotheadou E., Saloustros E.S., Koumarianou A., Athanasiadis I., Karageorgopoulou S., Papakotoulas P., Syrios I., Kesisis G., Papadimitriou C., Biziota E., Skondra M., Giassas S., Kampletsas E., Peroukidis S., Christodoulou C., Papageorgiou F., Boukovinas I., Saridaki Z. (2022). Journal of Clinical Oncology, 40, Number 16_suppl.</i>
19.	1585P - Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies. Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumarianou A., Ardavanis A., Athanasiadis I., Demiri M., Bokas A., Samelis G.F., Peroukidis S., Papatsimpas G., Andreadis C., Nikolakopoulos A., Psyrris A., Kapodistrias N., Papakostas P., Aravantinos G., Athanasiadis A., Papakotoulas P., Boukovinas I. (2022). Annals of Oncology, 33(Suppl 7), p.S1270.

20.	P-214 - Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study. Tsoukalas N., Christopoulou A., Anastopoulou G., Papandreou C., Timotheadou E., Athanasiadis I., Koumariou A., Peroukidis S., Samelis G., Psyrri A., Kapodistrias N., Nikolakopoulos A., Andreadis C., Ardavanis A., Samantas E., Bokas A., Barbounis V., Kentepozidis N., Mavroudis D., Athanasiadis A., Papakotoulas P., Boukovinas I. (2021). <i>Annals of Oncology</i> , 32(Suppl 3), p.S172.
21.	1692P - Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention? Tsoukalas N.G., Christopoulou A.N., Timotheadou E., Koumariou A., Athanasiadis I., Peroukidis S., Samelis G.F., Psyrri A., Kapodistrias N., Nikolakopoulos A., Demiri S., Andreadis C., Ardavanis A., Sgouros I., Bokas A., Barbounis V., Kentepozidis N., Mavroudis D., Papakotoulas P., Boukovinas I. (2021). <i>Annals of Oncology</i> , 32(Suppl 5), p.S1183.
22.	Real-World Treatment Patterns and Outcomes for HR+/HER2- Metastatic Breast Cancer: Insights from a Greek Registry Study by the Hellenic Society of Medical Oncology. Boutis A., Agelaki S., Ardavanis A., Mavroudis D., Timotheadou E., Athanasiadis I., Kotteas E., Bobolaki I., Floros T., Karageorgopoulou S., Aravantinos G., Tsoukalas N., Samelis G., Tzovaras A., Dimitriadou A., Matsiakou F., Nikolaou M., Katsika L., Mala A., Chatzifoti N., Boukovinas I., Saridaki-Zoras Z. (2024) 7ο Ελληνικό Συνέδριο Ογκολογίας, Θεσσαλονίκη 24-27 Απριλίου 2024.
23.	EA8: Θρομβοπροφύλαξη με ενδιάμεσες ή προφυλακτικές δόσεις LMWHs σε περιπατητικούς ασθενείς με καρκίνο: Συνδυασμένα αποτελέσματα από τις μελέτες GMaT & ACT4CAT. • Τσουκαλάς Ν., Χριστοπούλου Α., Τιμοθεάδου Ε., Κουμαριανού Α., Αρδαβάνης Α., Αθανασιάδης Η., Μπόκας Α., Περουκίδης Σ., Κουμάκης Γ., Παπασιμπίνας Γ., Σαμέλης Γ., Ψυρρή Α., Καποδίστριας Ν., Νικολακόπουλος Α., Ανδρεάδης Χ., Παπακώστας Π., Αραβαντινός Γ., Ζήρας Ν., Σουγγιέρη Μ., Καλόφωνος Χ., Κεντεποζίδης Ν., Μπαρμπούνης Β., Σαμαντάς Ε., Μακρυντωνάκης Π., Μαλά Α., Πενθερουδάκης Γ., Δεμίρη Σ., Τριποδάκη Έ.-Σ., Παπανδρέου Χ., Μαυρουδής Δ., Αναστοπούλου Γ., Αρβανίτου Ε., Γκίκας Κ., Παπαδοπούλου Π., Νικολαΐδη Α., Καμπόλη Α., Κατσούλη Ε., Δημητριάδου Α., Γκολφινόπουλος Σ., Άσση Α., Μουζακίτη Α., Τζήμου Μ., Περδικάρη Κ.-Χ., Γιαννακάκου Μ., Λίτος Ι., Σοφατζής Ι., Μίχας Α., Μπίνας Ι., Κωσταρίδης Ε., Θαλασσινού Π., Λούλιας Ν., Αρδαβάνης-Λουκέρης Γ., Γκούμας Γ., Ιωάννου Σ., Καριανάκης Γ., Βολακάκης Ν., Πουλιάρης Α., Αθανασιάδης Α., Παπακοτούλας Π., Μπουκοβίνας Ι. (2024). 7ο Ελληνικό Συνέδριο Ογκολογίας, Θεσσαλονίκη, 24-27 Απριλίου 2024.

24.	EA7: Ηλεκτρονικό μητρώο καταγραφής διατροφικής κατάστασης και φροντίδας ατόμων με νεοπλασματική νόσο - Dietary Assessment Recording of Oncology Patients (DROP). • Τσίγκας Α., Γκιουλμπασάνης Ι., Βίδρα Ν., Λογοθέτης Μ., Γιαννακούλια Μ., Δημητρακόπουλος Γ., Τσουκαλάς Ν., Κοντογιάννη Μ. (2024). 7ο Ελληνικό Συνέδριο Ογκολογίας, Θεσσαλονίκη, 24-27 Απριλίου 2024.
25.	EA14: Δεδομένα καθημερινής κλινικής πρακτικής για τη θρομβοπροφύλαξη σε ασθενείς με ενεργό καρκίνο: Συγκεντρωτική ανάλυση των μελετών GMaT και ACT4CAT. • Τσουκαλάς Ν., Χριστοπούλου Α., Τιμοθεάδου Ε., Κουμαριανού Α., Αρδαβάνης Α., Αθανασιάδης Η., Μπόκας Α., Περουκίδης Σ., Κουμάκης Γ., Παπασιώμπος Γ., Σαμέλης Γ., Ψυρρή Α., Καποδίστριας Ν., Νικολακόπουλος Α., Ανδρεάδης Χ., Παπακώστας Π., Αραβαντινός Γ., Ζήρας Ν., Σουγγλέρη Μ., Καλόφωνος Χ., Κεντεποζίδης Ν., Μπαρμπούνης Β., Σαμαντάς Ε., Μακραντωνάκης Π., Μαλά Α., Πενθερουδάκης Γ., Δεμίρη Σ., Τριποδάκη Έ.-Σ., Παπανδρέου Χ., Μαυρουδής Δ., Αναστοπούλου Γ., Αρβανίτου Ε., Γκίκας Κ., Παπαδοπούλου Π., Νικολαΐδη Α., Καμπόλη Α., Κατσούλη Ε., Δημητριάδου Α., Γκολφινόπουλος Σ., Άσση Α., Μουζακίτη Α., Τζήμου Μ., Περδικάρη Κ.-Χ., Γιαννακάκου Μ., Λίτος Ι., Σοφατζής Ι., Μίχας Α., Μπίνας Ι., Κωσταρίδης Ε., Θαλασσινού Π., Λούλιας Ν., Αρδαβάνης-Λουκέρης Γ., Γκούμας Γ., Ιωάννου Σ., Καριανάκης Γ29ο Ελληνικό Συνέδριο Κλινικής Ογκολογίας, Αθήνα, 5-8 Απριλίου 2023., Βολακάκης Ν., Πουλιάκης Α., Αθανασιάδης Α., Παπακοτούλας Π., Μπουκοβίνας Ι. (2023). 29ο Ελληνικό Συνέδριο Κλινικής Ογκολογίας, Αθήνα, 5-8 Απριλίου 2023.

26.	ΕΑ12: Έλεγχος νεοδιαγνωσθέντων ασθενών με προχωρημένο υψηλόβαθμο καρκίνο των ωοθηκών (OC) με το διαγνωστικό τεστ Myriad Genetics MyChoice CDx PLUS υπογραμμίζει την ανάγκη για δημόσια ασφαλιστική κάλυψη των γενετικών εξετάσεων: Αποτελέσματα ενός εθνικού προγράμματος της ΕΟΠΕ • Λιόντος Μ., Τιμοθεάδου Ε., Σαλούστρος Εμ., Κουμαριανού Α., Αθανασιάδης Η., Καραγεωργοπούλου Σ., Παπακοτούλας Π., Σύριος Ι., Κεσίσης Γ., Παπαδημητρίου Χ., Μπιζιώτα Ε., Σκόνδρα Μ., Γιασσάς Σ., Καμπλέτσας Ε., Περουκίδης Σ., Χριστοδούλου Χ., Καντζιούρα Α., Νικολάου Μ., Παπαξοΐνης Γ., Σούπος Ν., Φωταρέλλη Α., Εμμανουηλίδης Χ., Κωτσάκης Α., Μαυρουδής Δ., Μπόκας Α., Σταματοπούλου Σ., Τόλης Χ., Mauri D., Αναγνωστόπουλος Α., Γεωργούλιας Β., Κοραντζής Ι., Κούτρας Α., Κουτσούκος Κ., Παπαδόπουλος Γ., Παπανικολάου Σ., Πούπτης Α., Ρωμανίδου Ο., Τουρούτογλου Ν., Τσιάρα Α., Φλώρος Θ., Αγοραστός Α., Αδαμίδης Α., Ανδρεάδης Χ., Ανδρεάδου Α., Γκούβερης Π., Δεμίρη Σ., Δημούδης Σ., Καλυκάκη Α., Καναλουπίτη Δ., Καποδίστριας Ν., Μακατσώρης Θ., Μούντζιος Ι., Μποτσόλης Κ., Νάση Δ., Ντουβέλης Ε., Ξανθάκης Ι., Οικονομοπούλου Π., Παπαζήσης Κ., Περδικούρη Ε.Ι., Πισπιρίγκου Μ., Πλοιαρχοπούλου Κ., Ραζή Ε., Ράλλης Γ., Ράπτη Κ., Σταμάτη Δ., Στεφάνου Δ., Τζαννίνης Δ., Τρυφωνόπουλος Δ., Φάσσας Α., Φούντζηλα Ε., Χαραλαμπάκης Ν., Χατσίδης Γ., Χριστοπούλου Α., Αραβαντινός Γ., Αρδαβάνης Α., Ευθυμιάδης Κ., Ζαγουρή Φ., Ζακοπούλου Ρ., Ζαρκαβέλης Γ., Ζαφειρίου Ζ., Ζιώγας Δ., Ζλατίντσι Σ., Θωμοπούλου Κ., Καλόφωνος Χ., Καλτσάς Σ., Καρανικιώτης Χ., Κατωπόδη Ο., Κοσμάς Χ., Κοσμίδης Π., Κουρούσης Χ., Κωσταδήμα Λ., Λαμπρόπουλος Σ., Λάσχος Κ., Λέββα Σ., Λιανός Ε., Μακραντωνάκης Π., Μαραγκός Χ., Μητσιμπόνας Ν., Μιχαλάκη Β., Μπαρμπούνης Β., Μπαφαλούκος Δ., Μπούτης Α., Νεανίδης Κ., Νικηφορίδης Λ., Νικολακόπουλος Α., Ντουφεξής Δ., Οικονομόπουλος Γ., Ορφανός Γ., Πάνου Μ., Παπαναστασάκης Π., Παπαφίλη Α., Παρασκευά Μ., Πεκτασίδη Ε., Πετράκης Δ., Πουπτής Α., Ρηγάκος Γ., Ρήγας Γ., Σπάθας Ν., Σφήκα Α., Τέγος Θ., Τζοβάρας Α., Τριποδάκη Ε.Σ., Τσουκαλάς Ν., Παπαγεωργίου Φ., Μπουκοβίνας Ι., Σαριδάκη Ζ. (2022). 6ο Ελληνικό Συνέδριο Ογκολογίας, Θεσσαλονίκη, 4-7 Μαΐου 2022.
27.	ΑΑ7: Πρόληψη της φλεβικής θρομβοεμβολής σε περιπατητικούς ασθενείς με ενεργό καρκίνο: Αποτελέσματα από τη μελέτη ACT4CAT • Τσουκαλάς Ν., Χριστοπούλου Α., Κουμαριανού Α., Τιμοθεάδου Ε., Αθανασιάδης Η., Σαμέλης Γ., Περουκίδης Σ., Ψυρρή Α., Καποδίστριας Ν., Νικολακόπουλος Α., Δεμίρη Σ., Ανδρεάδης Χ., Μπόκας Α., Τριποδάκη Ε.-Σ., Αρδαβάνης Α., Σαμαντάς Ε., Παπανδρέου Χ., Καλόφωνος Χ., Μαυρουδής Δ., Κεντεποζίδης Ν., Μπαρμπούνης Β., Αναστοπούλου Γ., Αρβανίτου Ε., Γκίκας Κ., Παπαδοπούλου Π., Νικολαΐδη Α., Καμπόλη Α., Κατσούλη Ε., Δημητριάδου Α., Γκολφινόπουλος Σ., Άσση Α., Μουζακίτη Ά., Τζήμου Μ., Περδικάρη Κ.-Χ., Γιαννακάκου Μ., Λίτος Ι., Σοφατζής Ι., Μαλά Α., Μίχας Α., Μπίνας Ι., Θαλασσινού Π., Λούλιας Ν., Αρδαβάνης-Λουκέρης Γ., Βολακάκης Ν., Αθανασιάδης Α., Παπακοτούλας Π., Μπουκοβίνας Ι. (2022) 6ο Ελληνικό Συνέδριο Ογκολογίας, Θεσσαλονίκη, 4-7 Μαΐου 2022.

Επιστημονικές πλήρεις δημοσιεύσεις σε διεθνή περιοδικά -PubMed Publications

1.	Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the VELOUR trial
2.	Understanding exceptional response: The role of MINDY1 SNP in CDK4/6 inhibitor therapy for ER+, HER2– advanced breast cancer, Eleni Balla, Yi Li, Zikun Zhou, John T. Nguyen, Kyriaki Papadopoulou, Evangelia Razis, Angelos Koutras, Eleni Galani, Giannis Mountzios, Ourania Romanidou, George Fountzilas, Athina Christopoulou, Dimitris Tryfonopoulos, Panagiota Oikonomopoulou, Zenia Saridaki, Anna Koumarianou, Elena Fountzilas, Leonidas Bleris. <i>Human Genetics and Genomics Advances</i> , 2026;7(1):100560.
3.	Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece <i>ESMO Gastrointestinal Oncology</i> , 2025;8:100153.
4.	Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study <i>ESMO Real World Data and Digital Oncology</i> , 2025;7:100095.
5.	Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer <i>ESMO Gastrointestinal Oncology</i> , 2024;5:100073.
6.	Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report, Zacharenia Saridaki, Elena Fountzilas, Athanasios Alexopoulos, Niki Karachaliou, BMC Medical Genomics, Volume 18, article number 51, (2025)
7.	Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns, Elena Fountzilas, Theofanis Papadopoulos, Eirini Papadopoulou, Cedric Gouedard, Helen P Kourea, Pantelis Constantoulakis, Christina Magkou, Maria Sfakianaki, Vassiliki Kotoula, Dimitra Bantouna, Georgia Raptou, Angelica A Saetta, Georgia Christopoulou, Dimitris Hatzibougias, Electra Michalopoulou-Manoloutsiou, Eleni Siatra, Eleftherios Eleftheriadis, Evangelia Kavoura, Loukas Kaklamanis, Antigoni Sourla, George Papaxoinis, Kitty Pavlakis, Prodromos Hytiroglou, Christina Vourlakou, Petroula Arapantoni-Dadioti, Samuel Murray, George Nasioulas, Grigorios Timologos, George Fountzilas, Zacharenia Saridaki, <i>Diagnostics</i> 14 (11), 1076
8.	Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer, Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsoulos, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, Florentia Fostira, George Fountzilas, Michalis Lontos, <i>Cancers</i> 15(23), 5525
9.	Vaccine third dose and cancer patients: necessity or luxury?, G Pappas, E Saloustros, A Boutis, N Tsoukalas, M Nikolaou, A Christopoulou, S Agelaki, I Boukovinas, A Ardavanis, Z Saridaki, <i>ESMO open</i> 6 (6), 100306
10.	Responses to SARS-CoV-2 vaccination in patients with cancer (ReCOVer study): a prospective cohort study of the Hellenic Cooperative Oncology Group, Helena Linardou, Nikolaos Spanakis, Georgia-Angeliki Koliou, Athina Christopoulou, Sofia Karageorgopoulou,

	Nephely Alevra, Anastasios Vagionas, Nikolaos Tsoukalas, Stavroula Sgourou, Elena Fountzilas, Joseph Sgouros, Evangelia Razis, Dimitra Chatzokou, Sofia Lampaki, Zacharenia Saridaki, Giannis Mountzios, George Saroglou, George Fountzilas, Cancers 13 (18), 4621
11.	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer, Giannis Mountzios, E Samantas, Karsten Senghas, E Zervas, Johannes Krisam, K Samitas, Farastuk Bozorgmehr, Jonas Kuon, S Agelaki, S Baka, I Athanasiadis, Lena Gaißmaier, Mariam Elshiaty, Lea Daniello, A Christopoulou, G Pentheroudakis, E Lianos, H Linardou, Katharina Kriegsmann, P Kosmidis, Rami El Shafie, Mark Kriegsmann, A Psyrris, C Andreadis, E Fountzilas, C-P Heussel, FJ Herth, Hauke Winter, C Emmanouilides, G Oikonomopoulos, Michael Meister, Thomas Muley, Helge Bischoff, Z Saridaki, E Razis, E-I Perdikouri, Albrecht Stenzinger, I Boukovinas, M Reck, K Syrigos, Michael Thomas, Petros Christopoulos, ESMO open 6 (5), 100254
12.	Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma, Elena Fountzilas, Alexia Eliades, Georgia-Angeliki Koliou, Achilleas Achilleos, Charalambos Loizides, Kyriakos Tsangaras, Dimitrios Pectasides, Joseph Sgouros, Pavlos Papakostas, Grigorios Rallis, Amanda Psyrris, Christos Papadimitriou, Georgios Oikonomopoulos, Konstantinos Ferentinos, Anna Koumarianou, George Zarkavelis, Christos Dervenis, Gerasimos Aravantinos, Dimitrios Bafaloukos, Paris Kosmidis, George Papaxoinis, Maria Theochari, Ioannis Varthalitis, Nikolaos Kentepozidis, Georgios Rigakos, Zacharenia Saridaki, Adamantia Nikolaidi, Athina Christopoulou, Florentia Fostira, Epaminontas Samantas, Elena Kypri, Marios Ioannides, George Koumbaris, George Fountzilas, Philippos C Patsalis, Cancers 13 (2), 198
13.	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group, Elena Fountzilas, Georgia-Angeliki Koliou, Athanassios Vozikis, Vassiliki Rapti, Achilleas Nikolakopoulos, Anastasios Boutis, Athina Christopoulou, Ioannis Kontogiorgos, Sofia Karageorgopoulou, Efthalia Lalla, Dimitrios Tryfonopoulos, Ioannis Boukovinas, Cleopatra Rapti, Adamantia Nikolaidi, Sofia Karteri, Evangelia Moirogiorgou, Ioannis Binas, Davide Mauri, Gerasimos Aravantinos, Flora Zagouri, Zacharenia Saridaki, Amanda Psyrris, Dimitrios Bafaloukos, Anna Koumarianou, Helena Linardou, Giannis Mountzios, Evangelia Razis, George Fountzilas, Georgios Koumakis, ESMO open 5 (4), e000774
14.	PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer, M Sfakianaki, C Papadaki, M Tzardi, M Trypaki, S Manolakou, I Messaritakis, Z Saridaki, D Mavroudis, V Georgoulas, J Souglakos, Annals of Oncology 30, iv21-iv22
15.	Association of notch and hedgehog pathway activation with prognosis in early-stage colorectal cancer, Grigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, Kyriaki Manousou, Georgia-Angeliki Koliou, Ioannis Kostopoulos, Vassiliki Kotoula, Thomas Makatsoris, Helen P Kourea, Georgia Raptou, Sofia Chrisafi, Epaminontas Samantas, Kleo Papaparaskeva, Elissavet Pazarli, Pavlos Papakostas, Georgia Kafiri, Davide Mauri, Alexandra Papoudou-Bai, Christos Christodoulou, Kalliopi Petraki, Nikolaos Dombros, Dimitrios Pectasides, George Fountzilas, Anticancer Research 39 (4), 2129-2138
16.	Colchicum genus in the writings of ancient Greek and Byzantine physicians, Gregory Tsoucalas, Theodoros Papaioannou, George Panayiotakopoulos, Zenia Saridaki, Dimitrios A Vrachatis, Marianna Karamanou, Current pharmaceutical design 24 (6), 648-653

17.	Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy, S Pontikakis, C Papadaki, M Tzardi, M Trypaki, M Sfakianaki, F Koinis, E Lagoudaki, L Giannikaki, A Kalykaki, E Kontopodis, Z Saridaki, N Malamos, V Georgoulas, J Souglakos, The pharmacogenomics journal 17 (6), 506-514
18.	Reduced expression of SMAD4 is associated with poor survival in colon cancer, Pu Yan, Dirk Klingbiel, Zenia Saridaki, Paola Ceppa, Monica Curto, Thomas Alexander McKee, Arnaud Roth, Sabine Tejpar, Mauro Delorenzi, Fredrik T Bosman, Roberto Fiocca, Clinical Cancer Research 22 (12), 3037-3047
19.	Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma, Zacharenia Saridaki, Georgia Lambrodinou, Stefanos Kachris, Paris Makrantonakis, Ioannis Boukovinas, Aris Polyzos, Athanasios Anagnostopoulos, Athanasios Athanasiadis, Dimitris Stoltidis, Vassilis Georgoulas, John Souglakos, American Journal of Clinical Oncology 38 (1), 17-22
20.	Avenzoar's (1091-1162) clinical description of cancer, M Karamanou, G Tsoucalas, Z Saridaki, C Iavazzo, G Androutsos, J BUON 20 (4), 1171-4
21.	René-Théophile-Hyacinthe Laennec (1781-1826) and the description of metastatic pulmonary melanoma, M Karamanou, AJ Stratigos, Z Saridaki, G Tsoucalas, G Androutsos, J BUON 20 (1), 354-6
22.	KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?, Z Saridaki, X Saegart, Veerle De Vriendt, D Hatzidaki, Sander Palmans, Linde De Smedt, Gert De Hertogh, Sabine Tejpar, British Journal of Cancer 113 (6), 914-920
23.	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, D Klingbiel, Z Saridaki, AD Roth, FT Bosman, M Delorenzi, Sabine Tejpar, Annals of oncology 26(1), 126-132
24.	Cost-effectiveness analysis of panitumumab+ mFOLFOX over bevacizumab+ mFOLFOX as a first-line treatment for metastatic colorectal cancer patients with wild-type RAS in Greece, G Kourlaba, I Boukovinas, Z Saridaki, V Papagiannopoulou, G Tritaki, N Maniadas, Value in Health 17 (7), A633
25.	ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples Expressão ERCC1 Correlacionada com EGFR e Variáveis Clínicas em Doentes com Carcinoma Pulmonar de Não Pequenas Células. Um estudo imunocitoquímico em amostras biópsias aspirativas por agulha fina, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, Z Saridaki, M Tzardi, Revista Portuguesa de Pneumologia (English Edition) 20(4), 200-207
26.	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy, Zenia Saridaki, Joanne B Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, Sabine Tejpar, Clinical Cancer Research 20 (17), 4499-4510

27.	Prognostic and predictive significance of MSI in stages II/III colon cancer, Z Saridaki, J Souglakos, V Georgoulas, Z Saridaki, J Souglakos, V Georgoulas, World Journal of Gastroenterology: WJG 20 (22), 6809
28.	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome, Zacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, Chara Papadaki, Alexandra Voutsina, Aristeia Kalykaki, Ippokratis Messaritakis, Kyriakos Mpananis, Dimitris Mavroudis, Efsthios Stathopoulos, Vassilis Georgoulas, John Souglakos, PloS one 8 (12), e84604
29.	The eminent dermatologist Moriz Kaposi (1837-1902) and the first description of idiopathic multiple pigmented sarcoma of the skin, M Karamanou, C Antoniou, AJ Stratigos, Z Saridaki, G Androutsos, J buon 18 (4), 1101-5
30.	The great surgeon Jean-Louis Faure (1863-1944) and his contribution in the treatment of uterine cancer, M Karamanou, Z Saridaki, M Piagkou, K Laios, G Androutsos, J BUON 18 (1), 296-298
31.	Aretaeus of Cappadocia and the first description of diabetes, K Laios, M Karamanou, Z Saridaki, G Androutsos, Hormones 11, 109-113
32.	A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial, Z Saridaki, N Androulakis, N Vardakis, L Vamvakas, E Kabouraki, K Kalbakis, D Hatzidaki, A Voutsina, D Mavroudis, V Georgoulas, J Souglakos, British journal of cancer 107 (12), 1932-1937
33.	A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer, Zacharenia Saridaki, Nikolaos Malamos, Panagiotis Kourakos, Aristides Polyzos, Alexandros Ardavanis, Nikolaos Androulakis, Kostas Kalbakis, Lambros Vamvakas, Vassilis Georgoulas, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 69, 35-42
34.	Cytopathologic interpretation of ascites due to malignancy, A Kalogeraki, I Karvela-Kalogeraki, D Tamiolakis, P Petraki, A Papathanasiou, Z Saridaki, EN Stathopoulos, M Tzardi, J buon 17 (3), 446-51
35.	Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients, Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristeia Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efsthios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulas, John Souglakos, PloS one 6 (1), e15980
36.	Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle, S Tejpar, Z Saridaki, M Delorenzi, F Bosman, AD Roth, Journal of the National Cancer Institute 103 (11), 841-844
37.	Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer, Nikolaos Vardakis, Ippokratis Messaritakis, Chara Papadaki, Georgios Agoglossakis, Maria Sfakianaki, Zacharenia Saridaki, Stella Apostolaki, Ioannis Koutroubakis, Maria Perraki, Dora Hatzidaki, Dimitris Mavroudis, Vassilis Georgoulas, John Souglakos, Clinical Cancer Research 17 (1), 165-173
38.	Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer, E Saloustros, K Kalbakis, N Vardakis, A Kalykaki, G Milaki, M Rovithi, S Agelaki, Z Saridaki, V Georgoulas, D Mavroudis, J BUON 16 (2), 215-8

39.	Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study, Athanasios G Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvakas, Nikolaos Vardakis, Zacharenia Saridaki, George Samonis, Stylianos Giassas, Vassilis Georgoulas, Sophia Agelaki, Clinical Lung Cancer 12 (2), 100-105
40.	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer, Panayiotis A Theodoropoulos, Hara Polioudaki, Sofia Agelaki, Galatea Kallergi, Zacharenia Saridaki, Dimitris Mavroudis, Vassilis Georgoulas, Cancer letters 288 (1), 99-106
41.	BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome, Z Saridaki, D Papadatos-Pastos, M Tzardi, D Mavroudis, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulas, J Souglakos, British journal of cancer 102 (12), 1762-1768
42.	Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer, Zacharenia Saridaki, Vassilis Georgoulas, John Souglakos, World journal of gastroenterology: WJG 16 (10), 1177
43.	A retrospective analysis of non-platinum-based first-and second-line chemotherapy in patients with advanced non-small cell lung cancer, Athanasios Kotsakis, Dora Hatzidaki, Lambros Vamvakas, Nikolaos Vardakis, Antonia Kalykaki, Vasiliki Bozionelou, Nikolaos Androulakis, Kostas Kalbakis, Zacharenia Saridaki, Vassilis Georgoulas, Sophia Agelaki, Anticancer research 30 (10), 4335-4342
44.	Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study, Charalambos Kouroussis, Lambros Vamvakas, Nikolaos Vardakis, Athanasios Kotsakis, Antonia Kalykaki, Kostas Kalbakis, Zacharenia Saridaki, Nikolaos Kentepozidis, Stelios Giassas, Vassilis Georgoulas, Oncology 76 (2), 112-117
45.	A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors, Zacharenia Saridaki, Periklis Pappas, John Souglakos, Martha Nikolaidou, Nikolaos Vardakis, Athanasios Kotsakis, Marios Marselos, Vassilis Georgoulas, Dimitris Mavroudis, Cancer chemotherapy and pharmacology 65, 121-128
46.	Prognostic and predictive significance of BRAF mutation in patients with metastatic colorectal cancer treated with 5-fluorouracil-based 1st line chemotherapy, Z Saridaki, M Tzardi, D Papadatos-Pastos, E Kampouraki, E Zois, E Stathopoulos, V Georgoulas, D Mavroudis, J Souglakos, EJC Supplements 2 (7), 91-92
47.	Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial, Ioannis Gioulbasanis, Zacharenia Saridaki, Antonia Kalykaki, Lambros Vamvakas, Kostas Kalbakis, Michail Ignatiadis, Kyriakos Amarantidis, Stylianos Kakolyris, Vassilis Georgoulas, Dimitris Mavroudis, Anticancer research 28 (5B), 3019-3025
48.	A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors, Zacharenia Saridaki, Vasiliki Bozionelou, Nikolaos Kentepozidis, Athanasios Kotsakis, Nikolaos Vardakis, Antonia Kalykaki, Ioannis Gioulbasanis, Athanasios Karampeazis, Lambros Vamvakas, Vassilis Georgoulas, Dimitris Mavroudis, Oncology 72 (1-2), 45-50

49.	Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract, I Gkioulbasanis, J Souglakos, N Vardakis, A Kotsakis, Z Saridaki, N Kentepozidis, A Polyzos, S Giassas, Michail Ignatiadis, V Bozionelou, C Christophylakis, Vassilis Georgoulis, JOURNAL-BALKAN UNION OF ONCOLOGY 12 (2), 197
50.	A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors, A Kalykaki, L Vamvakas, Sofia Agelaki, K Kalbakis, N Vardakis, G Sfakiotaki, Michail Ignatiadis, Z Saridaki, A Karampeazis, D Mavroudis, V Georgoulis, Oncology 71 (3-4), 197-203 10 2007
51.	Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status, John Souglakos, Lambros Vamvakas, Stella Apostolaki, Maria Perraki, Zacharenia Saridaki, Irine Kazakou, Athanasios Pallis, Charalambos Kouroussis, Nikos Androulakis, Kostas Kalbakis, Georgia Millaki, Dimitris Mavroudis, Vassilis Georgoulis, Breast Cancer Research 8 (4), 1-8
52.	Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors, Ch Kouroussis, N Androulakis, L Vamvakas, A Kalykaki, S Spiridonakou, N Kentepozidis, Z Saridaki, El Xiropoulou, V Georgoulis, Oncology 69 (3), 202-207
53.	Idiopathic CD4+ T lymphocytopenia disclosed by recurrent cryptococcal meningitis. First case report from Greece, Diamantis P Kofteridis, Zacharenia Saridaki, Ireni Kazakou, Silvia Lazaridou, Dimitris Alegakis, Georgia Milaki, Achilleas Gikas, International Journal of Infectious Diseases 9 (6), 347-348
54.	A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-fluorouracil in patients with advanced solid tumors, John Souglakos, Stylianos Kakolyris, Nikolaos Vardakis, Nikolaos Androulakis, Dimitrios Mavroudis, Lambos Vamvakas, Charalambos Kouroussis, Sophia Agelaki, Zacharenia Saridaki, Vassilis Georgoulis, Cancer investigation 23 (6), 505-510
55.	Endothelial p21WAF1/Cip1 cell cycle inhibitor is down-regulated in breast cancer, T Vrekoussis, EN Stathopoulos, M Kafousi, Z Saridaki, E Sanidas, O Zoras, Anticancer research 25 (4), 2743-2748
56.	Intestinal ischemia as the first manifestation of vasculitis, Freda H Passam, Ioannis D Diamantis, Garyfalia Perisinaki, Zenia Saridaki, Herakles Kritikos, Dimitrios Georgopoulos, Dimitrios T Boumpas, Seminars in arthritis and rheumatism 34 (1), 431-441
57.	Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin, Z Saridaki, T Liloglou, A Zafiropoulos, E Koumantaki, O Zoras, DA Spandidos, British Journal of Dermatology 148 (4), 638-648
58.	First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer, G Fiorentini, D Tsetis, P Bernardeschi, C Varveris, S Rossi, A Kalogeraki, E Athanasakis, P Dentico, P Kanellos, M Biancalani, S Almarashdah, G Zacharioudakis, Z Saridaki, G Chalkiadakis, E Xynos, O Zoras, Anticancer research 23 (5), 4339-4346
59.	Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction, DP Kofteridis, S Karabekios, JG Panagiotides, J Bizakis, D Kyrmizakis, Z Saridaki, A Gikas, Journal of chemotherapy 15 (3), 282-286

60.	Surgical repair of incisional ventral hernias: tension-free technique using prosthetic materials (expanded polytetrafluoroethylene Gore-Tex Dual Mesh), Emmanuel Chrysos, Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Dimitra Dimitriadou, Vasilios Koutsoumpas, George Chalkiadakis, Evangelos Xynos, Odysseas Zoras, The American Surgeon 66 (7), 679-682
61.	High frequency of loss of heterozygosity on chromosome region 9p21–p22 but lack of p16INK4a/p19ARF mutations in Greek patients with basal cell carcinoma of the skin, Zacharenia Saridaki, George Sourvinos, Demetrios A Spandidos, Elma Koumantaki, Triantafillos Liloglou, Othon Papadopoulos, Odysseas Zoras, Journal of investigative dermatology 115 (4), 719-725
62.	Surgical repair of inguinal hernia: tension free technique with prosthetic materials (Gore-Tex Mycro Mesh expanded polytetrafluoroethylene), Elias Athanasakis, Zenia Saridaki, Alexandros Kafetzakis, Emmanuel Chrysos, George Prokopakis, Nickolaos Vrahasotakis, Evangelos Xynos, George Chalkiadakis, Odysseas Zoras, The American Surgeon 66 (8), 728-731